A toxic adenoma is a benign, autonomously functioning thyroid nodule that produces excess thyroid hormones independent of TSH regulation, resulting in hyperthyroidism.

Exam domain	One-glance essentials
Definition / diagnosis	*Toxic adenoma* is a solitary benign follicular neoplasm producing thyroid hormone autonomously, independent of TSH ^[1] It causes true primary hyperthyroidism, not merely thyrotoxicosis from hormone release or ingestion ^[1] Distinguish from Graves disease and toxic multinodular goitre ^[1]
Epidemiology / risks	More common with older age, nodular thyroid disease and iodine deficiency ^[1] Progression is more likely with a larger nodule, older age, or an acute iodine load such as contrast or amiodarone ^[1] Activating somatic TSHR/GNAS pathway mutations produce autonomy ^[1]
Core mechanism	Constitutive receptor/G-protein signalling increases cAMP and thyroid hormone synthesis despite suppressed TSH ^[1] Autonomous hormone excess suppresses the surrounding normal thyroid tissue ^[1] Smaller nodules may cause subclinical hyperthyroidism; enlargement may cause overt disease ^[1]
Clinical picture	Solitary, usually painless anterior neck nodule with symptoms of thyrotoxicosis: weight loss, heat intolerance, palpitations and tremor ^[1] Apathetic thyrotoxicosis may present in older adults with atrial fibrillation, heart failure or unexplained weight loss ^[1] Graves-specific ophthalmopathy, pretibial myxoedema and diffuse bruit are absent ^[1] Sudden pain/enlargement suggests haemorrhage; hoarseness or lymphadenopathy is a malignancy red flag ^[1]
Investigations	First-line TFTs: TSH, free T4 and T3; suppressed TSH with raised hormones indicates overt disease ^[1] Suppressed TSH with normal free T4/T3 is subclinical hyperthyroidism; check T3 to exclude T3-toxicosis ^[1] *Scintigraphy is the key test when TSH is suppressed with a thyroid nodule* ^[1] *Focal increased uptake with suppressed surrounding tissue is diagnostic of toxic adenoma*; ultrasound assesses structure and the contralateral lobe ^[1]
Management	Use a beta-blocker for symptomatic control; antithyroid drugs are a temporary bridge, not curative ^[2] *Definitive treatment is radioactive iodine or surgery; RAI is preferred when there are no compressive or cancer indications ^[2] Hemithyroidectomy* is appropriate if the opposite lobe has no significant nodules; choose surgery for compression, suspicious cancer or preference ^[2] Render the patient euthyroid before surgery to reduce thyroid-storm risk ^[2]
Complications	Cardiovascular: atrial fibrillation, high-output heart failure and worsening ischaemia ^[1] Skeletal/metabolic: osteoporosis, mild hypercalcaemia and thyrotoxic periodic paralysis ^[1] Untreated disease or acute stress may precipitate *thyroid storm*, a life-threatening emergency ^[2] Treatment risks include ATD agranulocytosis/hepatotoxicity, RAI hypothyroidism and surgical RLN injury ^[2]
Prevention / follow-up	Treat definitive disease rather than relying on prolonged ATDs, which recur when stopped ^[2] Avoid unnecessary iodine loads, including contrast or amiodarone where alternatives exist ^[1] Before RAI, exclude pregnancy; avoid pregnancy and breastfeeding for the recommended post-treatment interval ^[2] Monitor TFTs after RAI or surgery for recurrent hyperthyroidism or hypothyroidism ^[2]
Exam traps	Low TSH plus a nodule does not prove toxic adenoma: Graves disease with an incidental nodule and toxic MNG require scintigraphy ^[1] *Hot nodules are almost never malignant*, but a cold or suspicious nodule requires ultrasound risk assessment and FNAC ^[1] Do not treat destructive thyroiditis with ATDs: it has low uptake and is self-limiting ^[1] Toxic adenoma rarely remits; antithyroid drugs control hormone synthesis only while taken ^[2]

References

^[1] Lecture slides: GC 177. A thyroid nodule benign thyroid nodules; thyroid cancer.pdf (p4–5) ^[2] Senior notes: felixlai.md (Section VI — Treatment of hyperthyroidism, Case study — RAI preparation)

Toxic Adenoma

A toxic adenoma (also known as toxic/functioning adenoma ^[1] or autonomously functioning thyroid nodule, AFTN) is a single, benign thyroid neoplasm — specifically a follicular adenoma — that has acquired the ability to produce thyroid hormones independently of TSH stimulation. The word "toxic" here means it is causing thyrotoxicosis (i.e. clinical thyroid hormone excess), not that the nodule itself is poisonous.

Let's break the name down:

"Toxic" = causing thyrotoxicosis (excess thyroid hormones in the blood)
"Adenoma" = a benign glandular neoplasm (Greek: adēn = gland, -oma = tumour)

This is distinct from:

Toxic multinodular goitre (MNG) — multiple autonomously functioning nodules (Plummer's disease in its original usage refers to toxic nodular goitre) ^[1]
Graves' disease — diffuse autoimmune hyperthyroidism
Non-toxic adenoma — a follicular adenoma that does NOT produce excess hormones (the vast majority of follicular adenomas are non-toxic) ^[1]

Key Distinction

Thyrotoxicosis ≠ Hyperthyroidism ^[2]^[3]. Thyrotoxicosis is the clinical syndrome of thyroid hormone excess from ANY cause (including exogenous T4 ingestion or destructive thyroiditis releasing stored hormone). Hyperthyroidism specifically refers to endogenous overactivity of the thyroid gland. A toxic adenoma causes true hyperthyroidism — the nodule is actively synthesising and secreting excess T3/T4.

2. Epidemiology

Toxic adenoma accounts for approximately 3–5% of all cases of thyrotoxicosis overall, though this varies geographically.
In iodine-deficient regions, it is more common (up to 5–10% of thyrotoxicosis), because iodine deficiency promotes nodular thyroid disease and increases the chance of autonomous nodules developing.
In iodine-sufficient regions (including most of Hong Kong), Graves' disease dominates (~70–80% of thyrotoxicosis), and toxic adenoma is less common (~3–5%).
Benign follicular adenoma: mainly non-toxic (15%) of all thyroid nodules ^[1] — most adenomas do NOT become toxic. Only a minority acquire activating mutations and gain autonomous function.

Sex: Female > Male (approximately 4–6:1), as with most thyroid diseases.
Age: Typically presents in adults aged 30–60 years, with a peak in middle age. Less common in children.
In Hong Kong, thyroid nodules are extraordinarily common (prevalence depends on method of detection: 3–7% by palpation, > 30% if by autopsy/USG) ^[4], but only a small fraction are toxic adenomas.

Risk Factor	Mechanism
Iodine deficiency (historical/geographical)	Chronic TSH stimulation → nodular hyperplasia → increased chance of somatic activating mutations
Female sex	Oestrogen may promote thyroid cell proliferation; general predisposition to thyroid disease
Increasing age	Cumulative exposure to TSH stimulation and time for somatic mutations to accumulate
Pre-existing thyroid nodules / MNG	A nodule in a multinodular goitre can acquire autonomous function
Family history of thyroid disease	Genetic predisposition to nodular thyroid disease

Hong Kong Context

Hong Kong is generally considered iodine-sufficient (due to iodised salt and seafood consumption), so Graves' disease is the dominant cause of thyrotoxicosis here. However, toxic adenoma and toxic MNG still occur, particularly in older patients and those from backgrounds with historical iodine deficiency (e.g. migrants from inland China).

3. Anatomy and Function — The Thyroid Gland

The thyroid is a butterfly-shaped endocrine gland located in the anterior neck, overlying the 2nd–4th tracheal rings.
It consists of two lateral lobes connected by an isthmus.
Blood supply: superior thyroid artery (from external carotid) and inferior thyroid artery (from thyrocervical trunk). The gland is highly vascular.
Important adjacent structures:
- Recurrent laryngeal nerves (RLN): run in the tracheo-oesophageal groove — injury causes hoarseness
- Parathyroid glands: four small glands on posterior thyroid surface — injury causes hypocalcaemia
- Trachea and oesophagus: may be compressed by large nodules

The thyroid is composed of follicles — spherical structures lined by a single layer of follicular epithelial cells surrounding a central lumen filled with colloid (thyroglobulin-rich proteinaceous material).
Follicular cells are responsible for:
1. Iodine trapping: via the sodium-iodide symporter (NIS) on the basolateral membrane
2. Thyroglobulin (Tg) synthesis: secreted into the colloid
3. Iodine organification: iodide is oxidised by thyroid peroxidase (TPO) and attached to tyrosine residues on Tg → forms monoiodotyrosine (MIT) and diiodotyrosine (DIT)
4. Coupling: MIT + DIT → T3; DIT + DIT → T4
5. Secretion: colloid is endocytosed, Tg is proteolysed, and free T3/T4 are released into the blood

The TSH receptor is a G-protein coupled receptor (GPCR) on the basolateral surface of follicular cells.
Normally, TSH from the anterior pituitary binds TSH-R → activates Gsα → stimulates adenylyl cyclase → ↑cAMP → activates protein kinase A (PKA) → promotes:
- Iodine uptake (NIS expression)
- Thyroglobulin synthesis
- Hormone synthesis and secretion
- Follicular cell growth and proliferation
In a toxic adenoma, the TSH-R (or Gsα) is constitutively activated due to a somatic gain-of-function mutation — meaning it is "always on" regardless of whether TSH is bound to it.

4. Etiology and Pathophysiology

A toxic adenoma arises because a single follicular cell acquires a somatic (not germline) activating mutation that causes constitutive activation of the TSH signalling pathway. This cell then clonally expands into an autonomous nodule.

The two most important mutations:

Mutation	Frequency	Mechanism
TSH receptor (TSHR) gene mutation	~60–70% of toxic adenomas	Gain-of-function point mutation in the transmembrane domain → receptor is locked in the "active" conformation → constitutive activation of Gsα → ↑cAMP even without TSH binding
Gsα (GNAS1) gene mutation	~5–10% of toxic adenomas	Gain-of-function mutation in the alpha subunit of the stimulatory G-protein → GTPase activity impaired → Gsα remains active → constitutive ↑cAMP

These are the same mutations (particularly Gsα) seen in McCune-Albright syndrome (a mosaic condition with constitutive Gsα activation causing polyostotic fibrous dysplasia, café-au-lait spots, and precocious puberty — and sometimes thyroid autonomy) ^[2].

Let me walk through this step by step:

Mutation occurs → a single follicular cell gains a constitutively active TSHR or Gsα.
Autonomous hormone production → this cell (and its clonal progeny) produce T3/T4 regardless of TSH levels. The more the nodule grows, the more hormone it produces.
Negative feedback → elevated T3/T4 feeds back to the hypothalamus and anterior pituitary → TSH is suppressed (often to undetectable levels).
Normal thyroid tissue is suppressed → because TSH is the trophic hormone for normal follicular cells, the rest of the thyroid gland receives no stimulation → it becomes quiescent/atrophic. This is why on a thyroid scintigraphy scan, you see a "hot" (high-uptake) nodule with "cold" (suppressed) surrounding tissue.
Progressive hormone excess → as the nodule grows, it produces more and more hormone → eventually causes overt thyrotoxicosis.

Small autonomous nodules ( < 2.5–3 cm) may produce enough hormone to suppress TSH but not enough to elevate free T4/T3 above normal → this is subclinical hyperthyroidism (↓TSH, normal fT4/T3) ^[3]^[4].
As the nodule enlarges (typically > 3 cm), hormone production exceeds the body's capacity to compensate → overt thyrotoxicosis (↓TSH, ↑fT4/T3).
Subclinical hyperthyroidism: most commonly elderly with toxic MNG ^[4] — but toxic adenoma can also present this way.
Toxic adenomas almost never undergo malignant transformation — hot nodules are almost never malignant ^[5].
Progression to thyrotoxicosis is more likely with larger nodules, iodine supplementation (e.g. contrast agents, amiodarone), and in older patients.

Why does iodine loading precipitate thyrotoxicosis in autonomous nodules?

An autonomous nodule has active NIS and is avidly trapping iodine. Normally, the thyroid has a protective mechanism called the Wolff-Chaikoff effect — high iodine levels transiently inhibit organification. However, autonomous nodules may escape this inhibition more readily, and the sudden abundance of substrate (iodine) allows the already constitutively active synthetic machinery to produce a surge of thyroid hormones → Jod-Basedow phenomenon (iodine-induced thyrotoxicosis). This is clinically relevant when patients with nodular thyroid disease undergo CT with iodinated contrast or are started on amiodarone (which is 37% iodine by weight).

TSHR and Gsα mutations promote differentiation and function (hormone production, iodine uptake) rather than dedifferentiation.
In contrast, thyroid cancers typically arise from mutations in pathways promoting proliferation and dedifferentiation (e.g. BRAF, RAS, RET/PTC rearrangements) — these tend to LOSE the ability to take up iodine and produce hormones efficiently.
Therefore: a nodule that is "hot" (functioning, taking up radioiodine) is almost by definition well-differentiated and functional → overwhelmingly benign. The risk of malignancy in a hot nodule is < 1–2%.

5. Classification

Toxic adenoma belongs to primary hyperthyroidism — the thyroid gland itself is overactive ^[2]:

Category	Causes
Primary hyperthyroidism	Graves' disease (diffuse toxic goitre), Toxic multinodular goitre, Toxic adenoma, Metastatic thyroid cancer, Mutation of TSH receptor (germline), Mutation of Gsα (McCune-Albright syndrome) ^[2]
Secondary hyperthyroidism	TSH-secreting pituitary adenoma, Chorionic gonadotropin-secreting tumour, Gestational thyrotoxicosis ^[2]
Thyrotoxicosis without hyperthyroidism	Subacute (De Quervain's) thyroiditis, Silent thyroiditis, Destructive thyroiditis (amiodarone, irradiation), Levothyroxine overdose ^[2]

From the lecture classification ^[1]:

Category	Examples
Simple goitre (endemic or sporadic)	Diffuse, Nodular
Toxic goitre	Diffuse toxic (Graves'); Toxic nodular (Plummer's); Toxic/functioning adenoma
Neoplastic goitre	Benign, Malignant
Thyroiditis	Bacterial (acute suppurative), Viral (subacute), Lymphocytic/Hashimoto/autoimmune (chronic)

Category	Examples
Solitary nodule	Dominant nodule in MNG; Cyst (true simple cyst, colloid nodule); Neoplastic: adenoma, toxic adenoma, carcinoma ^[6]
Multiple nodules	MNG (hyperplastic/adenomatous nodules with varying cystic degeneration), toxic MNG; Cyst (multiple); Neoplastic: multiple adenoma ^[6]
Diffuse	Graves' disease; Physiological (pregnancy, puberty); Hashimoto's thyroiditis; De Quervain's/subacute thyroiditis ^[6]

Scintigraphy Pattern	Interpretation
Focal ↑uptake with ↓uptake elsewhere	→ Toxic adenoma ^[5]
Diffuse ↑uptake	→ Graves' disease vs secondary hyperthyroidism ^[5]
Heterogeneous ↑uptake	→ Toxic MNG ^[5]
Diffuse ↓uptake	→ Destructive thyroiditis vs factitious thyrotoxicosis ^[5]

6. Clinical Features

The clinical features of a toxic adenoma are a combination of:

Local effects of the thyroid nodule itself (a palpable neck lump)
Systemic effects of thyrotoxicosis (due to excess circulating T3/T4)

The systemic features are identical to thyrotoxicosis from any cause, but certain features specific to Graves' disease (ophthalmopathy, pretibial myxoedema, thyroid acropachy) are absent — because these are autoimmune phenomena driven by TRAb acting on orbital/dermal fibroblasts, not simply due to excess thyroid hormones.

6A. Symptoms

Symptom	Pathophysiological Basis
Neck swelling / palpable lump ^[4]	Physical mass effect of the growing adenoma; patients or family members may notice asymmetric anterior neck swelling
Pain or discomfort (uncommon) ^[4]	Acute painful enlargement can arise from haemorrhage into nodule/cyst ^[4] — sudden expansion stretches the capsule. Simple toxic adenomas are usually painless.
Dysphagia (difficulty swallowing) ^[4]	Local pressure symptoms ^[4] — large nodule compresses the oesophagus posteriorly. The oesophagus is relatively fixed and does not tolerate external compression well.
Dyspnoea / stridor ^[4]	Local pressure symptoms ^[4] — compression or deviation of the trachea, especially with large or retrosternal nodules
Dysphonia (hoarseness) ^[4]	Local pressure symptoms ^[4] — compression of the recurrent laryngeal nerve. In a benign adenoma this is very rare and should raise suspicion for malignancy if present.

Red Flag

Hoarseness (dysphonia) in a patient with a thyroid nodule is an alarming sign. Benign adenomas, even toxic ones, almost never cause RLN palsy because they are encapsulated and expand by pushing rather than invading. A hoarse voice should prompt consideration of thyroid carcinoma invading the RLN.

The excess T3/T4 increases basal metabolic rate (BMR), enhances catecholamine sensitivity (upregulation of β-adrenergic receptors), and accelerates nearly every metabolic process.

Symptom	Pathophysiological Basis
Weight loss despite normal/increased appetite	↑BMR → ↑caloric expenditure exceeding intake. T3/T4 stimulate both lipolysis and proteolysis.
Heat intolerance and sweating	↑BMR → ↑thermogenesis. T3 upregulates uncoupling proteins in mitochondria and increases peripheral vasodilation to dissipate heat → sweating.
Palpitations	T3 ↑cardiac β1-receptor expression → ↑heart rate and contractility. Also ↑sensitivity to circulating catecholamines.
Tremor (fine resting tremor of hands)	↑β-adrenergic stimulation of skeletal muscle → enhanced physiological tremor
Anxiety, irritability, emotional lability	T3 has direct CNS excitatory effects + ↑catecholamine sensitivity in the brain
Insomnia	CNS hyperexcitability from excess thyroid hormone
Increased frequency of bowel movements / diarrhoea	T3 ↑GI motility by stimulating smooth muscle contractility and gut transit time
Oligomenorrhoea or amenorrhoea (women)	T3 excess → ↑SHBG → altered oestrogen/progesterone metabolism; also direct effects on HPG axis
Erectile dysfunction / gynecomastia (men)	↑SHBG → altered androgen/oestrogen balance
Proximal muscle weakness	Thyroid myopathy — excess T3 accelerates protein catabolism in skeletal muscle; also altered muscle metabolism
Dyspnoea on exertion	↑oxygen demand + respiratory muscle weakness
Fatigue	Despite hypermetabolism, patients feel exhausted due to muscle wasting and sleep disturbance

Elderly Patients — Apathetic Thyrotoxicosis

Cardiopulmonary symptoms may dominate in older patients ^[3]. Elderly patients with toxic adenoma may NOT present with the classic hyperadrenergic features. Instead, they may present with AF, heart failure, or unexplained weight loss — so-called "apathetic thyrotoxicosis." Always check TFTs in elderly patients with new-onset AF or unexplained weight loss.

6B. Signs

Sign	Description and Pathophysiological Basis
Solitary, well-defined thyroid nodule	The adenoma is encapsulated, usually 2–5 cm (must be > ~1 cm to be palpable). Moves with swallowing (as it is part of the thyroid gland, which is attached to the pretracheal fascia).
Smooth, firm, non-tender	Follicular adenomas have a well-defined fibrous capsule and uniform follicular architecture → smooth surface, firm consistency. Pain is unusual unless haemorrhage occurs.
No thyroid bruit (unlike Graves')	In Graves' disease, the entire gland is hypervascular due to TSH-receptor antibody stimulation → audible bruit. In toxic adenoma, only the nodule is active; the rest of the gland is suppressed and less vascular.
Rest of thyroid may feel small/atrophic	TSH suppression → normal thyroid tissue is unstimulated → may atrophy over time
Tracheal deviation (if large nodule)	Mass effect pushing the trachea to the contralateral side

Physical examination of the thyroid should assess: ^[6]

Inspection: Surgical scar, swallowing test, tongue tug test
Voice hoarseness
Palpation: Diffuse vs solitary nodule vs MNG vs dominant nodule in MNG; Size; Consistency; Location; Lower border; Cervical LN; Trachea
General exam: Eye signs, Hands (tremor, sweating, tachycardia), Lower limbs (proximal muscle weakness, myxoedema)

Sign	Pathophysiological Basis
Tachycardia / AF	T3 ↑β1-receptor density in cardiac myocytes → ↑chronotropy; also shortens atrial refractory period → predisposes to AF
Wide pulse pressure / systolic hypertension	↑cardiac output + ↓peripheral vascular resistance (peripheral vasodilation for heat dissipation)
Warm, moist skin	Peripheral vasodilation + ↑sweating for thermoregulation
Fine tremor of outstretched hands	↑β-adrenergic stimulation
Lid retraction	Due to overactive sympathetic activity (↑Müller's muscle contraction) ^[3] — Müller's muscle (superior tarsal muscle) is smooth muscle innervated by sympathetic fibres; excess thyroid hormone ↑sympathetic tone → ↑contraction → upper lid retracts, exposing sclera above limbus. Not specific to Graves' disease ^[3] — can occur in ANY cause of thyrotoxicosis including toxic adenoma.
Lid lag	Due to overactive sympathetic activity (↑Müller's muscle contraction) ^[3] — on downgaze, the upper lid lags behind the globe. Same mechanism as lid retraction. Not specific to Graves' disease ^[3].
Hyperreflexia	↑neuronal excitability from excess T3 → brisk tendon reflexes with rapid relaxation phase
Proximal myopathy	Thyroid hormone-induced protein catabolism in skeletal muscle; test by asking patient to rise from a squat without using hands
Onycholysis (Plummer's nails)	Separation of nail from nail bed — the mechanism is not fully understood but is associated with thyrotoxicosis; possibly related to accelerated nail growth outpacing adhesion
Palmar erythema	Peripheral vasodilation

This is a crucial distinguishing point:

Sign	Why It Is Absent
Graves' ophthalmopathy (exophthalmos, ophthalmoplegia, chemosis, periorbital oedema)	This is an autoimmune process driven by TRAb binding to TSH receptors on orbital fibroblasts → inflammation, adipogenesis, glycosaminoglycan accumulation → ↑retroorbital tissue volume. Toxic adenoma has no TRAb → no ophthalmopathy.
Pretibial myxoedema	TRAb-mediated stimulation of dermal fibroblasts in the pretibial region → GAG deposition. Absent in toxic adenoma.
Thyroid acropachy	Periosteal hypertrophy clinically indistinguishable from finger clubbing ^[3] — autoimmune mediated, specific to Graves'.
Diffuse goitre with thyroid bruit	Graves' causes diffuse gland enlargement with markedly increased vascularity → bruit. Toxic adenoma is a solitary nodule.

How to Clinically Distinguish Toxic Adenoma from Graves' Disease

Feature	Toxic Adenoma	Graves' Disease
Goitre	Solitary nodule	Diffuse, non-tender, vascular
Thyroid bruit	Absent	Present
Ophthalmopathy	Absent	Present (~20–25%)
Pretibial myxoedema	Absent	Present ( < 10%)
Thyroid acropachy	Absent	Possible (rare)
Age	Typically older (30–60)	Younger (20–50)
TRAb	Negative	Positive (~100%)
Scintigraphy	Focal hot nodule, cold surround	Diffuse increased uptake

7. Approach to a Patient with Suspected Toxic Adenoma

A patient presents with a palpable solitary thyroid nodule and symptoms/signs of thyrotoxicosis but WITHOUT Graves'-specific features (no ophthalmopathy, no diffuse goitre, no bruit).

History: Assess for thyrotoxic symptoms (weight loss, heat intolerance, palpitations, tremor, anxiety, bowel changes), local symptoms (neck swelling, dysphagia, dyspnoea, hoarseness), and risk factors for thyroid malignancy (prior neck irradiation, FHx of CA thyroid: MENII, FAP) ^[6].
Examination: Focused thyroid examination (solitary nodule? size? consistency? tenderness? cervical lymphadenopathy? tracheal deviation?) + systemic signs of thyrotoxicosis (heart rate, rhythm, tremor, lid retraction, lid lag, proximal myopathy). Specifically look for and document the ABSENCE of Graves'-specific signs.
Thyroid function tests (TFTs): TSH is the most sensitive test ^[3].
- ↓TSH, ↑fT4, ↑T3 → overt thyrotoxicosis
- ↓TSH, normal fT4/T3 → subclinical hyperthyroidism
Etiological investigations: Once thyrotoxicosis is confirmed biochemically and a nodule is palpable:
- Thyroid scintigraphy ^[5] → the KEY investigation to confirm toxic adenoma:
  - Focal ↑uptake with ↓uptake elsewhere → toxic adenoma ^[5]
  - This is the pathognomonic finding
- Thyroid ultrasound → assess nodule characteristics, look for features suspicious for malignancy (although hot nodules are almost never malignant), and check the contralateral lobe for additional nodules
- TRAb → should be negative (if positive, think Graves' with a coincidental nodule)

High Yield: In the event of ↓TSH with thyroid nodule(s), thyroid scintigraphy is indicated to differentiate between Graves' disease with co-existent thyroid nodule, toxic thyroid adenoma, and toxic MNG, and to determine the functional status of the dominant nodule ^[5]. Hot nodules are almost never malignant ^[5] — therefore FNAC may not be necessary for a confirmed hot nodule.

FNAC: Generally NOT required for a confirmed hot/functioning nodule on scintigraphy (because < 1–2% malignancy risk). FNAC is reserved for nodules that are "cold" (non-functioning) or have suspicious ultrasound features.

Pathophysiology	→	Clinical Feature
Somatic TSHR/Gsα mutation → constitutive cAMP activation	→	Autonomous hormone production, nodule growth
Excess T3/T4 → ↑BMR	→	Weight loss, heat intolerance, sweating
Excess T3/T4 → ↑β-adrenergic sensitivity	→	Tachycardia, AF, tremor, lid retraction, lid lag, anxiety
Excess T3/T4 → ↑cardiac output, ↓SVR	→	Wide pulse pressure, systolic hypertension, warm skin
Excess T3/T4 → ↑GI motility	→	Frequent stools / diarrhoea
Excess T3/T4 → ↑protein catabolism	→	Proximal myopathy, weight loss
TSH suppression → normal thyroid quiescent	→	Focal hot nodule on scintigraphy, rest of gland suppressed
Encapsulated adenoma → mass effect	→	Palpable neck lump, dysphagia, dyspnoea (if large)
No TRAb (not autoimmune)	→	NO ophthalmopathy, NO pretibial myxoedema

High Yield Summary

Toxic adenoma = a single benign follicular adenoma with a somatic gain-of-function mutation in TSHR (~60–70%) or Gsα (~5–10%) → constitutive cAMP activation → autonomous T3/T4 production independent of TSH.
Epidemiology: 3–5% of thyrotoxicosis; F > M; middle-aged adults; more common in iodine-deficient areas.
Key pathophysiology: Autonomous hormone production → ↑fT4/T3 → negative feedback → ↓↓TSH → suppression of normal thyroid tissue → focal hot nodule with cold surround on scintigraphy (pathognomonic).
Clinical features: Solitary, smooth, non-tender thyroid nodule + systemic thyrotoxicosis (weight loss, heat intolerance, palpitations, tremor, AF) but NO Graves'-specific features (no ophthalmopathy, no pretibial myxoedema, no diffuse goitre/bruit).
Lid retraction and lid lag can occur (sympathetic overactivity) — not specific to Graves' disease ^[3].
Hot nodules are almost never malignant ^[5] — FNAC usually not required for confirmed hot nodules.
Thyroid scintigraphy is the key etiological investigation when ↓TSH + thyroid nodule: focal ↑uptake with ↓uptake elsewhere → toxic adenoma ^[5].
Small nodules may present as subclinical hyperthyroidism (↓TSH, normal fT4/T3) before progressing to overt thyrotoxicosis.

Active Recall - Toxic Adenoma: Definition, Epidemiology, Etiology, Pathophysiology and Clinical Features

^[1] Lecture slides: GC 177. A thyroid nodule benign thyroid nodules; thyroid cancer.pdf (p4–5) ^[2] Senior notes: felixlai.md (Section III — Causes of thyrotoxicosis) ^[3] Senior notes: Ryan Ho Endocrine.pdf (p12, p17, p23) ^[4] Senior notes: Ryan Ho Endocrine.pdf (p17 — Goitre and Thyroid Nodules; p31 — Thyroiditis) ^[5] Senior notes: Adrian Lui Pediatrics.pdf (p271–272 — Etiological Ix, Thyroid scintigraphy) ^[6] Senior notes: maxim.md (Approach to thyroid nodules — DDx, Physical examination)

Differential Diagnosis of Toxic Adenoma

When a patient presents with a thyroid nodule and/or thyrotoxicosis, you are not immediately handed the diagnosis of "toxic adenoma" on a silver platter. You need to systematically work through the differential. The DDx spans two overlapping clinical problems:

What is causing the thyrotoxicosis? (if TFTs are deranged)
What is this thyroid nodule? (if a lump is palpable or found incidentally)

These two questions converge — a toxic adenoma sits at the intersection — but they each have their own differential list, and occasionally a patient has both a non-functioning nodule AND a separate cause of thyrotoxicosis (e.g. Graves' disease with a coincidental cold nodule). The clinical and investigative challenge is to determine whether the nodule IS the cause of the thyrotoxicosis, or whether they are unrelated.

This is the framework from the evaluation flowchart ^[7]. When you confirm biochemical thyrotoxicosis, you must determine the aetiology — is the thyroid hyperactive (true hyperthyroidism), is stored hormone leaking out (destructive thyroiditis), or is the patient taking exogenous hormone?

Systematic Classification of Causes of Thyrotoxicosis

Category	Condition	Key Distinguishing Features
Primary hyperthyroidism (thyroid overactive)	Graves' disease	Diffuse toxic goitre with bruit; ophthalmopathy, pretibial myxoedema ^[3]; TRAb positive; scintigraphy: diffuse ↑uptake ^[5]
	Toxic multinodular goitre (Plummer's) ^[1]	Multiple palpable nodules; usually older patients; scintigraphy: heterogeneous ↑uptake ^[5]; long-standing MNG with autonomous nodules
	Toxic adenoma (the index condition)	Solitary palpable nodule; no Graves'-specific signs; scintigraphy: focal ↑uptake with ↓uptake elsewhere ^[5]^[8]
	Metastatic thyroid cancer (rare)	Large tumour burden of well-differentiated follicular CA with functioning metastases
	Mutation of TSH receptor (germline) ^[2]	Familial non-autoimmune hyperthyroidism; presents in childhood; diffuse goitre
	Mutation of Gsα (McCune-Albright syndrome) ^[2]	Polyostotic fibrous dysplasia, café-au-lait spots, precocious puberty; mosaic activating GNAS1 mutation
Secondary hyperthyroidism (TSH-driven)	TSH-secreting pituitary adenoma ^[2]^[7]	↑TSH, ↑fT4, ↑T3 ^[7] — TSH is NOT suppressed (this is the distinguishing biochemical clue); may have visual field defects from pituitary mass
	Chorionic gonadotropin-secreting tumour ^[2]	hCG structurally mimics TSH → stimulates TSH-R; associated with hydatidiform mole or choriocarcinoma
	Gestational thyrotoxicosis ^[2]	Physiological ↑hCG in early pregnancy (peak 10–12 weeks) → transient TSH suppression; usually mild and self-limiting; associated with hyperemesis gravidarum
Thyrotoxicosis WITHOUT hyperthyroidism (destructive or exogenous)	Subacute (De Quervain's) thyroiditis ^[2]	Preceding URTI, fever, tender goitre ^[3]; self-limiting thyrotoxic → hypothyroid → recovery phases; scintigraphy: diffuse ↓uptake ^[5]
	Silent/painless thyroiditis	Autoimmune; painless goitre; scintigraphy: diffuse ↓uptake
	Postpartum thyroiditis	Recent ( < 6 months) pregnancy ^[3]; same triphasic course as silent thyroiditis
	Destructive thyroiditis (amiodarone, irradiation) ^[2]	Drug/radiation-induced follicular destruction → release of stored T3/T4; scintigraphy: ↓uptake
	Levothyroxine (T4) overdose / factitious thyrotoxicosis ^[2]	Intake of ANY medications (esp slimming pills) ^[3]; confirmed by ↑T4:T3 ratio ( > 70:1 vs 30:1 in conventional thyrotoxicosis) and ↓serum thyroglobulin ^[5]

Why Does the T4:T3 Ratio Help Identify Factitious Thyrotoxicosis?

In endogenous hyperthyroidism, the thyroid gland secretes both T4 and T3 directly (and T3 is also produced by peripheral deiodination of T4). In exogenous T4 ingestion, the patient's own thyroid is suppressed (no endogenous T3 secretion), and ALL circulating T3 comes from peripheral conversion of the ingested T4. Since conversion is rate-limited, the T4:T3 ratio becomes disproportionately elevated ( > 70:1). Additionally, the suppressed thyroid produces no thyroglobulin → ↓serum thyroglobulin ^[5].

Around 10–15% of nodules are malignant ^[6] — the majority are benign. Here is the systematic DDx of a thyroid nodule:

Category	Differential	Key Features
Solitary nodule ^[6]	Dominant nodule in MNG	On careful examination or USG, additional nodules are present in the contralateral lobe or isthmus
	Cyst: true simple cyst, colloid nodule ^[6]	Fluctuant; USG shows anechoic fluid-filled structure; usually euthyroid
	Neoplastic: adenoma (non-toxic) ^[1]^[6]	Benign follicular adenoma: mainly non-toxic (15%) ^[1]; encapsulated, smooth; euthyroid; scintigraphy: "warm" or "cold"
	Toxic adenoma ^[6]	Solitary functioning nodule; thyrotoxicosis; scintigraphy: hot nodule with suppressed surround
	Carcinoma ^[6]	Papillary (85%), follicular (10–15%), medullary (3%), anaplastic (1%) ^[6]; hard, irregular, fixed; cervical lymphadenopathy; scintigraphy: "cold" nodule
Multiple nodules ^[6]	MNG (hyperplastic/adenomatous nodules with varying degree of cystic degeneration) ^[6]	Most common cause of multiple thyroid nodules; may be euthyroid or toxic
	Toxic MNG ^[6]	Multiple autonomously functioning nodules; scintigraphy: heterogeneous ↑uptake
	Multiple adenomas	Less common; multiple encapsulated nodules
Diffuse ^[6]	Graves' disease	Diffuse goitre + thyroid bruit + ophthalmopathy; TRAb positive
	Physiological (pregnancy, puberty) ^[6]	Mild diffuse enlargement; euthyroid or mildly hyperthyroid
	Hashimoto's thyroiditis ^[6]	Firm, rubbery goitre; hypothyroid (or euthyroid early); anti-TPO and anti-Tg positive
	De Quervain's/subacute thyroiditis ^[6]	Tender, diffuse goitre; post-viral; elevated ESR

High Yield: Thyroid nodule pathology ^[1]: Nodular goitre: colloid/haemorrhagic cystic/complex/hyperplastic/adenomatous nodule (70%); Benign follicular adenoma: mainly non-toxic (15%); Well-differentiated thyroid carcinoma (10%); Miscellaneous: other thyroid malignancies, thyroiditis (5%) ^[1].

This is the key clinical scenario where the DDx becomes most relevant. When a patient presents with ↓TSH AND a thyroid nodule, you must distinguish between:

Scenario	Scintigraphy Finding	Interpretation
Toxic adenoma	Focal ↑uptake with ↓uptake elsewhere ^[5]^[8]	The nodule IS the cause of thyrotoxicosis
Toxic MNG	Heterogeneous ↑uptake ^[5]^[8]	Multiple hot nodules causing thyrotoxicosis
Graves' disease with coincidental nodule	Diffuse ↑uptake ^[5]^[8] with nodule that may be hot, warm, or cold	Graves' is causing the thyrotoxicosis; the nodule is incidental. If the nodule is COLD against a diffusely hot background, it may harbour malignancy → needs FNAC
Non-functioning nodule with unrelated thyrotoxicosis	Cold nodule + other pattern	The nodule is NOT causing the thyrotoxicosis; investigate both separately

This is WHY Thyroid Scintigraphy is Essential

In the event of ↓TSH with thyroid nodule(s), thyroid scintigraphy is indicated to differentiate between Graves' disease with co-existent thyroid nodule, toxic thyroid adenoma, and toxic MNG ^[5]. Without scintigraphy, you cannot reliably determine whether the nodule is functioning (hot) or non-functioning (cold). This distinction is critical because: (1) hot nodules are almost never malignant ^[5] → FNAC may be deferred; (2) cold nodules in a thyrotoxic patient may represent cancer and NEED FNAC; (3) management differs completely between these entities.

D. Differentiating Toxic Adenoma from Its Closest Mimics

Feature	Toxic Adenoma	Graves' Disease
Goitre	Solitary nodule	Diffuse, smooth, non-tender goitre
Thyroid bruit	Absent	Often present (increased vascularity)
Ophthalmopathy ^[9]	Absent	Present in ~20–25% (exophthalmos, ophthalmoplegia, chemosis)
Pretibial myxoedema	Absent	Present in < 10%
TRAb	Negative	Positive (~100% in active disease) ^[3]
Scintigraphy	Focal ↑uptake, ↓surround ^[5]^[8]	Diffuse ↑uptake ^[5]^[8]
Demographics	Older (30–60), often in nodular thyroid disease	Younger (20–50), women of reproductive age ^[3]
Thyrotoxic periodic paralysis	Possible (any cause of thyrotoxicosis)	More commonly associated ^[3]

Why this matters: Management is different. Graves' may be treated with a trial of antithyroid drugs for 12–18 months with a chance of remission. Toxic adenoma is unlikely to remit with antithyroid drugs — they merely control symptoms while you are taking them, and recur upon discontinuation ^[6]. Definitive treatment (surgery or RAI) is usually needed.

Feature	Toxic Adenoma	Toxic MNG
Number of nodules	Single	Multiple
Palpation	Solitary, discrete nodule	Irregular, multinodular gland
Scintigraphy	Focal ↑uptake ^[8]	Heterogeneous ↑uptake ^[5]
Typical patient	Younger than toxic MNG	Older, long-standing goitre
Surgery	Hemithyroidectomy (if no evidence of nodules in contralateral lobe) ^[6]	Total thyroidectomy ^[6]

Feature	Toxic Adenoma	Thyroid Carcinoma
Scintigraphy	Hot (functioning)	Cold (non-functioning)
Consistency	Smooth, firm, encapsulated	Hard, irregular, may be fixed
Cervical lymphadenopathy	Absent	May be present (especially papillary CA → level VI) ^[6]
Hoarseness	Very rare (benign lesion)	Possible (RLN invasion)
Malignancy risk	< 1–2%	By definition
TFTs	Thyrotoxic (↓TSH, ↑fT4)	Usually euthyroid
Microcalcifications on USG	Absent	Psammoma bodies in papillary CA

Feature	Toxic Adenoma	Subacute Thyroiditis
Pain	Painless (unless haemorrhage)	Tender goitre; pain may radiate to angle of jaw and ears ^[4]
Onset	Gradual (months)	Acute/subacute (weeks), preceded by URTI ^[3]^[4]
Systemic symptoms	Absent	Fever, ↑WBC, ↑ESR ^[4]
Scintigraphy	Focal ↑uptake ^[8]	Diffuse ↓uptake ^[5] (damaged follicles cannot trap iodine)
Course	Persistent/progressive	Self-limiting: thyrotoxic → hypothyroid → resolution ^[4]
Management	Definitive Tx needed	Self-limiting → do NOT give antithyroid medications ^[4]

Feature	Toxic Adenoma	Factitious Thyrotoxicosis
Thyroid gland	Palpable nodule	Usually normal or small (suppressed)
Scintigraphy	Focal ↑uptake	Diffuse ↓uptake ^[5] (exogenous hormone suppresses all thyroid function)
T4:T3 ratio	Normal (~30:1)	↑ ( > 70:1) ^[5]
Serum thyroglobulin	Normal or elevated	↓ (suppressed) ^[5]
History	—	Intake of ANY medications (esp slimming pills) ^[3]

This algorithm integrates the evaluation of thyrotoxicosis flowchart ^[7] with scintigraphy findings ^[5]^[8]:

Red Flag	Think Instead
Rapidly enlarging nodule with pain and hoarseness	Anaplastic carcinoma ^[3] (although extremely rare to be hot on scintigraphy)
Cervical lymphadenopathy	Thyroid carcinoma (papillary or medullary)
Ophthalmopathy or pretibial myxoedema present	Graves' disease (even if a nodule is palpable — it may be a coincidental non-functioning nodule)
Diffuse ↓uptake on scintigraphy	Not a toxic adenoma — think destructive thyroiditis or factitious thyrotoxicosis
Family history of MEN2, RET mutation	Medullary thyroid carcinoma (cold nodule, may present with elevated calcitonin)
History of head & neck irradiation	↑risk of papillary thyroid carcinoma
Clinical features suggesting ↑risk of malignancy: Male sex; Age < 14y or > 70y; Solitary firm/hard fixed nodule with progressive growth; Pressure symptoms/RLN palsy; Cervical LNs; Neck irradiation; FHx thyroid CA ^[3]	All warrant careful evaluation even if initial TFTs suggest thyrotoxicosis — a cold nodule adjacent to a hot one can be missed

High Yield Summary

The DDx of toxic adenoma spans two clinical problems: (a) causes of thyrotoxicosis, and (b) causes of a thyroid nodule. Toxic adenoma sits at the intersection.
Thyroid scintigraphy is the pivotal investigation when ↓TSH + nodule: focal ↑uptake with ↓uptake elsewhere = toxic adenoma; heterogeneous ↑uptake = toxic MNG; diffuse ↑uptake = Graves'; diffuse ↓uptake = destructive thyroiditis/factitious ^[5]^[8].
Graves' disease is the main DDx — distinguished by diffuse goitre with bruit, ophthalmopathy, pretibial myxoedema, positive TRAb, diffuse ↑uptake ^[3]^[5].
Toxic MNG is distinguished by multiple nodules and heterogeneous uptake on scintigraphy ^[5].
Subacute thyroiditis is distinguished by tender goitre, preceding URTI, fever, ↑ESR, diffuse ↓uptake ^[3]^[4]^[5].
Factitious thyrotoxicosis: ↑T4:T3 ratio ( > 70:1), ↓thyroglobulin, diffuse ↓uptake, history of medication/slimming pills ^[3]^[5].
Hot nodules are almost never malignant ^[5] — but a COLD nodule in a thyrotoxic patient (e.g. Graves' with coincidental nodule) DOES need FNAC.
Around 10–15% of thyroid nodules are malignant ^[6] — always consider malignancy in the DDx of any thyroid nodule, especially if hard, irregular, fixed, with lymphadenopathy or hoarseness.

Active Recall - Differential Diagnosis of Toxic Adenoma

References

^[1] Lecture slides: GC 177. A thyroid nodule benign thyroid nodules; thyroid cancer.pdf (p4–5, p13) ^[2] Senior notes: felixlai.md (Section III — Causes of thyrotoxicosis) ^[3] Senior notes: Ryan Ho Endocrine.pdf (p12, p17–18, p23) ^[4] Senior notes: Ryan Ho Endocrine.pdf (p31 — Thyroiditis) ^[5] Senior notes: Adrian Lui Pediatrics.pdf (p271–272 — Etiological Ix, Thyroid scintigraphy) ^[6] Senior notes: maxim.md (Approach to thyroid nodules — DDx, Thyrotoxicosis indications, Thyroid cancer) ^[7] Senior notes: felixlai.md (Section V — Diagnostic protocol, Evaluation of thyrotoxicosis flowchart) ^[8] Lecture slides: GC 177. A thyroid nodule benign thyroid nodules; thyroid cancer.pdf (p13 — Radio-isotope scintigraphy images) ^[9] Senior notes: Ryan Ho Opthalmology.pdf (p128 — Dysthyroid Eye Disease)

Framing the Diagnostic Approach

There is no single "diagnostic criterion" for toxic adenoma in the way there is for, say, rheumatoid arthritis or diabetes. Instead, the diagnosis is established by a convergence of evidence from three pillars:

Biochemical confirmation of thyrotoxicosis (TFTs)
Demonstration that a thyroid nodule is autonomously functioning (scintigraphy)
Exclusion of other causes (clinical features, TRAb, USG)

Think of it as a jigsaw: you need each piece to fit together. Let me walk through the diagnostic criteria, the stepwise algorithm, and every investigation modality in detail.

While there is no formalised "checklist," the diagnosis of toxic adenoma rests on fulfilling ALL of the following:

Criterion	What You Need	Why
1. Biochemical thyrotoxicosis OR subclinical hyperthyroidism	↓TSH (usually undetectable) ± ↑fT4 and/or ↑T3 ^[3]^[5]	The autonomous nodule is producing excess hormone → negative feedback suppresses TSH. Small nodules may only suppress TSH without elevating fT4/T3 (subclinical).
2. A thyroid nodule present	Palpable solitary nodule on examination and/or nodule on USG	There must be a structural lesion — otherwise you are dealing with Graves' or thyroiditis
3. Scintigraphy showing a hyperfunctioning ("hot") nodule with suppressed surrounding tissue	Focal ↑uptake with ↓uptake elsewhere → toxic adenoma ^[5]^[8]	This is the pathognomonic finding. It proves the nodule is autonomously producing hormone AND that the rest of the gland is suppressed (no TSH stimulation). This pattern excludes Graves' (diffuse uptake) and toxic MNG (heterogeneous uptake).
4. Absence of Graves'-specific features	No ophthalmopathy, no pretibial myxoedema, no diffuse goitre with bruit, TRAb negative	If present, the diagnosis is Graves' disease ± a coincidental nodule

The Scintigraphy is the Diagnostic Cornerstone

Without scintigraphy, you CANNOT definitively diagnose a toxic adenoma. A suppressed TSH + a palpable nodule could still be Graves' disease with a coincidental nodule, or a toxic MNG with one dominant nodule. Thyroid scintigraphy is indicated in the event of ↓TSH with thyroid nodule(s) to differentiate between Graves' disease with co-existent thyroid nodule, toxic thyroid adenoma, and toxic MNG ^[5]^[3]. The focal hot nodule with cold surround is pathognomonic.

Overt vs Subclinical Presentation

	Overt Toxic Adenoma	Subclinical Toxic Adenoma
TSH	↓ (usually undetectable) ^[3]^[5]	↓ (suppressed but may be detectable) ^[3]
fT4	↑	Normal ^[3]
T3	↑ (may be elevated before fT4 — "T3 thyrotoxicosis")	Normal ^[3]
Symptoms	Present (weight loss, palpitations, tremor, etc.)	Often absent or subtle
Nodule size	Typically > 3 cm	Often 2–3 cm
Clinical significance	Requires treatment	Monitor vs treat depending on risk (see below)

High Yield: ↓TSH, normal fT3, normal fT4 = subclinical hyperthyroidism ^[3]^[5]. If fT4 is normal but TSH is suppressed, always measure fT3 — some toxic adenomas preferentially secrete T3 ("T3 thyrotoxicosis") ^[7].

Here is the complete stepwise approach, from initial presentation to confirmed diagnosis:

Explanation of Each Step (First Principles)

Step 1 — TFT (TSH + fT4): TSH is the most sensitive test ^[3]^[5] because the hypothalamic-pituitary-thyroid axis amplifies small changes in thyroid hormone levels into large changes in TSH. Even a small autonomous hormone production will suppress TSH before fT4 rises above normal. That's why TSH is your screening gatekeeper.

Step 2 — Clinical Assessment: Before ordering expensive investigations, look at the patient. Graves' disease has specific autoimmune stigmata (ophthalmopathy, pretibial myxoedema, diffuse bruit) that toxic adenoma does not. If these are present and obvious, TRAb confirms Graves' and you may not even need scintigraphy.

Step 3 — Thyroid Scintigraphy: This is the pivotal investigation ^[5]^[8]^[10]. It is NOT recommended for routine diagnostic use ^[10] — it is specifically indicated when ↓TSH level + thyroid nodule(s) ^[10]^[3]. Why? Because:

If TSH is normal or elevated, the nodule cannot be hyperfunctioning (TSH is not suppressed, so there's no autonomous production overriding the axis). In euthyroid patients, you go straight to USG ± FNAC ^[10].
If TSH IS suppressed, you need to know whether the nodule is the source of the excess hormone.

Step 4 — USG Thyroid: Even though hot nodules almost never require FNAC ^[5]^[10], you still do USG to:

Characterise the nodule (size, composition)
Check the contralateral lobe for additional nodules (this affects surgical planning — hemithyroidectomy vs total thyroidectomy)
Identify any additional cold nodules that may need FNAC

3. Investigation Modalities — Detailed Breakdown

3A. Blood Tests

Blood tests: TSH + free T4 ^[1] — this is the first-line investigation for every thyroid patient.

Test	Expected Finding in Toxic Adenoma	Explanation
Serum TSH (ultrasensitive)	↓ or undetectable ^[3]^[5]	Autonomous T3/T4 production → negative feedback on thyrotrophs → TSH suppression. The pituitary is exquisitely sensitive — TSH drops before peripheral hormones rise above normal.
Free T4 (fT4)	↑ in overt; normal in subclinical	The autonomous nodule secretes T4 (and some T3). T4 is the major secretory product.
Free T3 (fT3)	↑ in overt; may be elevated before fT4	Some toxic adenomas have enhanced deiodination (T4→T3 conversion) within the nodule, leading to T3 thyrotoxicosis where T3 rises before T4. T3 should be checked if suspected hyperthyroidism with concurrent illness ^[3] to distinguish from sick euthyroid syndrome.

Interpretation of TFT Patterns ^[3]^[5]^[7]:

Pattern	Interpretation
↓TSH, ↑fT4, ↑T3	Diagnostic of thyrotoxicosis (TSH usually undetectable) ^[3]
↓TSH, normal fT4, normal T3	Subclinical hyperthyroidism ^[3]
↓TSH, normal fT4, ↑T3	T3 thyrotoxicosis — measure T3 whenever fT4 is normal but TSH is suppressed
↑TSH, ↑fT4, ↑T3	TSH-dependent hyperthyroidism (very rare, due to TSH-secreting pituitary adenomas) ^[3] — this is NOT toxic adenoma

Pitfall: Don't Forget to Measure T3!

If TSH is suppressed but fT4 is normal, many students stop and call it "subclinical hyperthyroidism." But you MUST measure fT3 — it may be elevated (T3 thyrotoxicosis), which changes the clinical picture. Sick euthyroidism can also cause low TSH with low/normal fT4 ^[3] — but in that setting, T3 is usually low ^[3] (because peripheral T4→T3 conversion is impaired by illness), which is the opposite of T3 thyrotoxicosis. Checking T3 helps distinguish the two.

Condition	TFT Pattern	How to Distinguish
Central hypothyroidism (pituitary/hypothalamic insufficiency)	↓TSH, ↓/normal fT4	fT4 is LOW, not high; clinical context of hypopituitarism
Sick euthyroidism	TSH low/low-normal, fT4 low/normal/high, T3 usually low ^[3]	Concurrent systemic illness; T3 characteristically low
Pregnancy	↓TSH (1st trimester) due to hCG mimicking TSH	Transient; usually mild; clinical context

TRAb (anti-TSHr): sensitivity 97%, specificity 99% with newer assays ^[3]^[5].

Scenario	TRAb Result	Interpretation
Toxic adenoma	Negative	No autoimmune pathology — the nodule functions autonomously due to somatic mutation, not antibody stimulation
Graves' disease	Positive	TRAb stimulates TSH-R on all follicular cells → diffuse hyperthyroidism
Graves' with coincidental nodule	Positive	This scenario requires scintigraphy to determine whether the nodule is hot or cold

TRAb is not routinely done ^[3] when the clinical picture is clear (e.g. obvious solitary hot nodule on scintigraphy). However, it is essential when:

The clinical picture is ambiguous (is this Graves' with a nodule, or a toxic adenoma?)
A diffuse toxic goitre with negative TRAb is found → suggests destructive thyroiditis, not Graves' ^[3]^[5]

3B. Thyroid Scintigraphy (Radionuclide Scan)

This is the key etiological investigation for toxic adenoma ^[5]^[8]^[10]^[11].

Main use: assess metabolic function of thyroid gland ^[11]
Principle: radioactive iodine is handled in the same manner as normal iodine. Level of uptake (and hence metabolic activity) reflected by localisation of radioactive iodine ^[11]
A nodule that is "hot" is avidly trapping iodine → it is metabolically active → functioning autonomously
A nodule that is "cold" is NOT trapping iodine → it is non-functional → needs evaluation for malignancy

Agent	Mechanism	Pros	Cons
99mTc pertechnetate	Iodine trapping only ^[11] — has a similar ionic size as iodide ion, allowing it to be taken up by NIS ^[11]	Widely available, quick, low cost, low radiation dose	Only shows trapping, NOT organification; rare discordant nodules (trap but don't organify)
123I	Trapping + organification ^[11]	More physiological; shows full iodine metabolism	More expensive, less available
131I	Trapping + organification ^[11]	Can be used for both diagnosis and therapy	Higher radiation dose; β-emission causes tissue damage; mainly used therapeutically

Thyroid scintigraphy is NOT recommended for routine diagnostic use ^[10]. It is specifically indicated in:

↓TSH level + thyroid nodule(s) ^[10]^[3] — to determine functional status:
- ↓TSH level indicates overt or subclinical hyperthyroidism and radionuclide scan can confirm whether this is due to a thyroid nodule that is hyperfunctioning (hot) ^[10]
Multinodular goitre — to determine functional status of different nodules ^[10]
When suspecting destructive thyroiditis ^[5]
Diffuse toxic goitre with negative TRAb ^[5] — to differentiate Graves' from thyroiditis

Not performed in euthyroid (normal TSH) or ↑TSH patients since the thyroid nodule will never be hyperfunctioning and will require USG ± FNAC to confirm anyways ^[10].

Scintigraphy Pattern	Diagnosis	Explanation
Focal ↑uptake with ↓uptake elsewhere	→ Toxic adenoma ^[5]^[8]	The autonomous nodule avidly traps iodine; the suppressed normal tissue (no TSH stimulation) does not
Diffuse ↑uptake	→ Graves' disease vs secondary hyperthyroidism ^[5]	In Graves', TRAb stimulates ALL follicular cells uniformly → entire gland is hyperactive
Heterogeneous ↑uptake	→ Toxic MNG ^[5]	Multiple nodules with varying degrees of autonomous function
Diffuse ↓uptake	→ Destructive thyroiditis vs factitious thyrotoxicosis ^[5]	In destructive thyroiditis, follicles are damaged → cannot trap iodine. In factitious, TSH is suppressed → whole gland is quiescent. Distinguish by: factitious confirmed by ↑T4:T3 ratio and ↓serum thyroglobulin ^[5]

Images are often obtained at anterior, left anterior oblique (LAO) and right anterior oblique (RAO) ^[11].

High Yield: Radio-isotope scintigraphy (I123 or Tc99m) — diagnosis of malignancy: low sensitivity and specificity — functional assessment in thyrotoxic patients ^[8]. In other words, scintigraphy is NOT good for diagnosing cancer (many benign nodules are also cold), but it IS the gold standard for determining functional status.

Why Hot Nodules Don't Need FNAC

Hyperfunctioning (hot) nodules (uptake is greater than surrounding thyroid tissues) are almost never malignant and hence do NOT require FNAC ^[10]. Cold nodules (uptake is less than surrounding thyroid tissues) have 10–20% risk of being cancer and hence require FNAC provided that sonographic criteria are met ^[10]. The biological reason: TSHR/Gsα mutations that drive toxic adenomas promote differentiation and function (iodine uptake), while cancer-driving mutations (BRAF, RAS) promote dedifferentiation and loss of iodine-handling capacity. A functioning nodule is, by its very nature, well-differentiated and almost certainly benign.

3C. Thyroid Ultrasound (USG)

USG thyroid: routine for ALL goitre/nodules ^[3]^[6]^[12] — this is a first-line investigation for any thyroid lump, regardless of TFT results.

Purpose	Details
Characterise the nodule	Size, composition (solid/cystic/mixed), echogenicity, margins, vascularity, calcifications
Assess contralateral lobe	Check for additional nodules → affects surgical decision (hemithyroidectomy if contralateral lobe clear vs total thyroidectomy if bilateral nodules) ^[6]
Cervical lymph nodes	Cervical LN (esp deep nodes, e.g. level VI nodes) ^[6] — evaluate for suspicious lymphadenopathy
Assess retrosternal extension	Important if the nodule is large or the lower border is not palpable
Guide FNAC	If any cold or suspicious area needs biopsy

Feature	Expected Finding	Explanation
Composition	Well-defined, solid or mixed (solid with cystic areas from degeneration)	Follicular adenomas are encapsulated neoplasms
Echogenicity	Isoechoic or hyperechoic	Well-differentiated follicular tissue; hypoechoic raises concern for malignancy
Margins	Smooth, well-defined with complete halo	The halo represents the compressed capsule; irregular margins suggest malignancy
Calcifications	Usually absent; may have coarse calcifications (benign)	Microcalcifications raise concern for papillary carcinoma (Psammoma bodies)
Vascularity	Increased peripheral ("ring") vascularity	Hyperfunctioning nodule has increased blood flow; intranodular vascularity is more concerning for malignancy
Shape	Wider than tall	Taller than wide shape is suspicious for malignancy ^[10]^[12]

This is important because even though the nodule is likely a hot adenoma, you need to know what to look for in case there is an ADDITIONAL suspicious nodule:

High risk of thyroid cancer ^[10]	Low risk of thyroid cancer ^[10]
Hypoechoic	Hyperechoic
Microcalcifications	Large coarse calcifications
Taller than wide	Wider than tall
Irregular margins / Incomplete halo	Spongiform appearance / Comet-tail shadowing
Central vascularity	Peripheral vascularity

Sonographic features suspicious of malignancy: "SHIT CME" ^[6] — mnemonic for: Solid, Hypoechoic, Irregular margins, Taller than wide, Calcification (micro), Microlobulated, Extrathyroidal extension — most important are solid and hypoechoic ^[6].

3D. Fine Needle Aspiration Cytology (FNAC)

FNAC is the single most important investigation for thyroid nodule if TSH is not depressed ^[3]^[12]. However, in the specific context of a confirmed hot nodule on scintigraphy, FNAC is usually NOT required.

Scenario	FNAC Needed?	Rationale
Confirmed hot nodule on scintigraphy	No — hot nodules do NOT require FNAC ^[10]	< 1–2% malignancy risk; the nodule is autonomous and well-differentiated
Cold nodule on scintigraphy	Yes — cold nodules require FNAC ^[10]	10–20% risk of being cancer ^[10]
Euthyroid nodule (normal TSH, no scintigraphy done)	Yes — based on USG risk stratification	Scintigraphy was not indicated (TSH normal), so functional status is unknown → FNAC based on USG features
Additional cold nodule found alongside hot nodule	Yes	The hot nodule is benign, but the cold nodule could be malignant

If FNAC IS performed (e.g. on an additional suspicious cold nodule), results are reported using the Bethesda System:

Class	Diagnostic Category	Cancer Risk	Management
I	Non-diagnostic	1–4%	Repeat FNA ^[10]
II	Benign	0–3%	Clinical follow-up ^[10]
III	AUS or FLUS	5–15%	Repeat FNA / Molecular testing / HemiT if AUS ×2 ^[3]
IV	Follicular neoplasm	15–30%	Hemithyroidectomy / Molecular testing ^[3]
V	Suspicious for malignancy	60–75%	Hemithyroidectomy + frozen section + total thyroidectomy ^[3]
VI	Malignant	97–99%	Total thyroidectomy ^[3]

Key Point: FNAC accuracy is 90–95% ^[3]. The major limitation is that histological demonstration of capsular or vascular invasion is required to diagnose whether a follicular lesion is benign or malignant ^[3]^[12] — FNAC cannot distinguish follicular adenoma from follicular carcinoma. This is why Bethesda IV ("follicular neoplasm") requires surgical excision for definitive diagnosis.

Investigations for thyroid nodule ^[1]: Blood tests: TSH + free T4; Ultrasound; FNAC (+ molecular testing); ESR, thyroid antibodies, calcitonin, genetic testing; Imaging: radioisotope scan, CT scan/MRI, PET scan; Endoscopy; Thyroidectomy: diagnostic + therapeutic ^[1].

Investigation	Indication	Key Findings / Interpretation
CXR (thoracic inlet) ^[8]	Large goitre, suspected retrosternal extension	Tracheal deviation, retrosternal soft tissue shadow, thoracic inlet narrowing
CT scan / MRI ^[8]	Retrosternal goitre ^[6] (cannot be visualised by USG; needed for surgical planning); locally advanced thyroid cancer ^[6] (delineation of important structures within cervical fascia)	Retrosternal extension, tracheal compression/deviation, relationship to great vessels. Note that iodinated contrast may affect post-op radioactive iodine body scan ^[3].
PET scan ^[8]	No diagnostic role ^[6] for benign thyroid nodules; occasionally useful in thyroid cancer staging	FDG-avid nodules are concerning for malignancy
Endoscopy ^[8]	Suspected RLN palsy (direct laryngoscopy); suspected oesophageal involvement	Direct laryngoscopy for RLN palsy ^[3]; vocal cord mobility assessment pre-operatively
Flow-volume loop study ^[3]	Suspected airway obstruction from large goitre	UAO results in a blunted flow-volume loop ^[3] — flattening of both inspiratory and expiratory curves indicates fixed upper airway obstruction
ESR, anti-thyroid antibodies ^[3]^[1]	Suspected thyroiditis	↑ESR in subacute thyroiditis; anti-TPO/anti-Tg positive in Hashimoto's
Calcitonin ^[1]	If Hx or clinical suspicion of familial medullary carcinoma or MEN2 ^[3]	Elevated calcitonin → medullary thyroid carcinoma
Serum thyroglobulin	Suspected factitious thyrotoxicosis	↓serum thyroglobulin in factitious ^[5] (suppressed thyroid produces no Tg); elevated in endogenous thyrotoxicosis
Genetic testing (RET mutation)	Suspected MEN2/familial MTC	All patients with MTC should be tested for RET mutation ^[10]

CT Contrast and Radioactive Iodine — A Practical Trap

If you plan to treat a toxic adenoma with radioactive iodine (RAI), do NOT order a CT with iodinated contrast beforehand. Iodinated contrast may affect post-operative radioactive iodine body scan ^[3] — the excess iodine from contrast saturates the NIS and competes with therapeutic 131I, reducing RAI uptake for at least 6–8 weeks. If CT is needed, use non-contrast or MRI instead, or ensure adequate washout time before RAI.

Investigation	Why NOT Needed
FNAC of the hot nodule	Hot nodules do NOT require FNAC ^[10] — < 1–2% malignancy risk
TRAb (routinely)	TRAb is expected to be negative; only needed if clinical picture is ambiguous
Scintigraphy in euthyroid patients	NOT performed in euthyroid (normal TSH) or ↑TSH ^[10] — the nodule cannot be hyperfunctioning if TSH is not suppressed
PET scan	No diagnostic role at all ^[6] for evaluating benign thyroid nodules

Adapted from the lecture framework ^[6]:

Investigation	Routine?	Selective?	When?
History + Physical examination	✓ ^[6]		Always
Thyroid function test (TSH + fT4)	✓ ^[6]		Always — routinely done to identify potentially toxic nodules ^[6]
USG thyroid	✓ ^[6]		Always — for ALL goitre/nodules ^[3]
FNAC		✓	Only for cold/suspicious nodules — NOT for confirmed hot nodules ^[10]
Thyroid scintigraphy		✓ — Only in toxic (↓TSH) + nodules ^[6]	When TSH is suppressed and a nodule is present
TRAb		✓	When etiology is unclear (no obvious Graves' features) ^[3]^[5]
CT scan		✓	Only when retrosternal goitre or locally advanced thyroid cancer ^[6]
PET scan		✗ (no diagnostic role) ^[6]	Not indicated for toxic adenoma

High Yield Summary

Diagnostic criteria for toxic adenoma = ↓TSH ± ↑fT4/T3 + solitary thyroid nodule + focal hot nodule with cold surround on scintigraphy ^[5]^[8] + absence of Graves'-specific features + negative TRAb.
TSH is the most sensitive test ^[3] — always the first investigation. If TSH is not suppressed, the nodule is NOT autonomously functioning.
Thyroid scintigraphy is NOT for routine use ^[10] — only indicated when ↓TSH + thyroid nodule ^[10]. It is the pathognomonic test for toxic adenoma.
Radiopharmaceuticals: 99mTc pertechnetate (iodine trapping only) or 123I/131I (trapping + organification) ^[11].
Hot nodules do NOT require FNAC ^[10] — < 1–2% malignancy risk. Cold nodules have 10–20% risk of cancer and require FNAC ^[10].
USG is routine for ALL goitre/nodules ^[3]^[6] — look for suspicious features using TI-RADS / "SHIT CME" mnemonic ^[6].
FNAC is the single most important Ix for thyroid nodule if TSH is not depressed ^[3] — reported using the Bethesda classification ^[3]^[10]^[12].
Selective investigations: CXR (retrosternal), CT/MRI (retrosternal or locally advanced cancer — avoid iodinated contrast if RAI planned ^[3]), direct laryngoscopy (RLN palsy), calcitonin (MTC suspicion).

Active Recall - Diagnosis and Investigation of Toxic Adenoma

^[1] Lecture slides: GC 177. A thyroid nodule benign thyroid nodules; thyroid cancer.pdf (p7, p13) ^[3] Senior notes: Ryan Ho Endocrine.pdf (p12–13, p17, p19–20) ^[5] Senior notes: Adrian Lui Pediatrics.pdf (p271–272) ^[6] Senior notes: maxim.md (Approach to thyroid nodules — Investigations, Thyrotoxicosis indications) ^[7] Senior notes: felixlai.md (Section V — Diagnostic protocol, Evaluation of thyrotoxicosis flowchart) ^[8] Lecture slides: GC 177. A thyroid nodule benign thyroid nodules; thyroid cancer.pdf (p13) ^[10] Senior notes: felixlai.md (Radionuclide scan indications, FNAC, Sonographic criteria) ^[11] Senior notes: Ryan Ho Diagnostic Radiology.pdf (p59 — Thyroid Scintigraphy) ^[12] Senior notes: Ryan Ho Fundamentals.pdf (p427–428)

Management Philosophy

Before diving into specific treatments, understand the fundamental management principle for toxic adenoma: unlike Graves' disease, where the underlying autoimmune process may spontaneously remit after 12–18 months of antithyroid drugs, a toxic adenoma has a somatic gain-of-function mutation that is permanent. The nodule will NEVER stop producing hormone on its own. Therefore:

Antithyroid drugs are ineffective for toxic adenoma and toxic MNG in the long term: they recur upon discontinuation ^[6]
Definitive treatment (destruction or removal of the autonomous nodule) is almost always needed
Antithyroid drugs serve only as a bridge — controlling thyrotoxicosis while preparing for definitive treatment or when definitive treatment is not immediately feasible

This is a crucial distinction from Graves' disease, where ATDs are first-line with a reasonable chance of lasting remission.

Management of thyrotoxicosis from toxic adenoma ^[5]^[3]:

Non-selective short-acting β-blocker (e.g. propranolol, nadolol) for short-term alleviation of S/S ^[3]^[5]
Antithyroid drugs (ATD), e.g. carbimazole, methimazole, propylthiouracil ^[3]^[5] — as bridge therapy
Definitive Tx, i.e. radioactive iodine (RAI) or thyroidectomy ^[3]^[5]

Summary comparison across thyrotoxicosis causes ^[6]:

	Graves'	Toxic MNG (Plummer's)	Toxic nodule
Antithyroid drugs	1st line	(Ineffective: recur upon discontinuation) Prolonged use if patient does not want RAI or surgery	Bridge only — recur upon discontinuation
Radioactive iodine	2nd line	Preferred if no 4C	Preferred if no compressive symptoms
Surgery	2nd line	Preferred if 4C	Hemithyroidectomy if large nodule, compressive symptoms, or preference

"4C" = indications for thyroidectomy: Cancer (confirmed or suspicious), Compressive symptoms, Cannot be treated medically, Cosmesis ^[3].

3. Treatment Modalities — Detailed Breakdown

Non-selective short-acting β-blocker (e.g. propranolol, nadolol) for short-term alleviation of S/S ^[3]^[5].

Feature	Details
Purpose	Rapid symptom relief while waiting for definitive treatment to take effect
Mechanism	Blocks β1 and β2 adrenergic receptors → ↓heart rate, ↓tremor, ↓anxiety, ↓sweating. Propranolol also has a minor additional effect: inhibits peripheral conversion of T4 → T3 (at high doses) because peripheral 5'-deiodinase is partially catecholamine-dependent
Drug of choice	Propranolol 20–40 mg TDS–QDS (non-selective, also blocks peripheral T4→T3 conversion)
Alternatives	Nadolol (longer-acting, once daily), atenolol 25–50 mg/d (β1-selective — less effect on T4→T3 but more convenient)
Duration	Short-term only — until euthyroid state is achieved by ATD or definitive treatment
Contraindications	Asthma/severe COPD (β2 blockade → bronchospasm), decompensated heart failure, severe bradycardia, heart block

Why non-selective? Because T3/T4 upregulate β1 AND β2 receptors. The sympathetic overactivity in thyrotoxicosis manifests through both — β1 (tachycardia, palpitations) and β2 (tremor, vasodilation). A non-selective blocker addresses both.

β-Blockers Do NOT Treat the Cause

β-Blockers provide only symptomatic relief. They do NOT reduce thyroid hormone production or address the autonomous nodule. They are a bridge, not a cure. Never use β-blockers as monotherapy long-term for toxic adenoma.

3B. Antithyroid Drugs (ATDs) — Bridge Therapy

Antithyroid drugs, e.g. carbimazole, methimazole, propylthiouracil ^[3]^[5].

Drug	Mechanism
Carbimazole / Methimazole (carbimazole is a pro-drug metabolised to methimazole)	Inhibition of TPO → ↓organification, ↓coupling → ↓T4 synthesis ^[3]. Blocks thyroid peroxidase, the enzyme that iodinates tyrosine residues on thyroglobulin and couples MIT+DIT to form T3/T4.
Propylthiouracil (PTU)	Same TPO inhibition as above PLUS ↓peripheral T4 to T3 conversion ^[3] (inhibits type 1 5'-deiodinase in peripheral tissues). Also has immunosuppressive effects (↓TRAb — relevant for Graves' but not toxic adenoma).

ATDs are ineffective for toxic adenoma in the long term: they recur upon discontinuation ^[6]. Here's the reasoning from first principles:

In Graves' disease, ATDs work on two levels: (1) block hormone synthesis, and (2) have immunosuppressive effects that may allow the autoimmune process to "burn out" → remission in ~40% after 12–18 months.
In toxic adenoma, the problem is a permanent somatic mutation in TSHR/Gsα → the nodule will ALWAYS be constitutively active. There is no autoimmune process to suppress. The moment you stop ATDs, the mutant follicular cells resume autonomous hormone production.

Therefore, ATDs are used in toxic adenoma only to:

Render the patient euthyroid before surgery (critical to avoid thyroid storm)
Control symptoms while awaiting RAI
Long-term low-dose maintenance if the patient refuses or is unfit for both RAI and surgery (uncommon)

Aspect	Details
Drug of choice	Prefer carbimazole over PTU: achieve euthyroid more rapidly, once daily dosing, ↓hepatotoxicity, ↓bitter taste ^[3]
When to prefer PTU	(1) 1st trimester of pregnancy (↓teratogenicity), (2) thyroid storm (↓peripheral conversion of T4→T3), (3) minor reactions to carbimazole ^[3]
Starting dose	Carbimazole 15–60 mg/d in 2–3 divided doses (depends on initial TFT) ^[3] with baseline CBC and LFT
Monitoring	Monitor TFT ± CBC/LFT Q4–6 weeks until euthyroid ^[3], then tail down to maintenance dose
Slow onset	Therapy given for 12–18 months [in Graves'] — onset of euthyroid takes 3–4 weeks since the thyroid gland has large storage of hormones — hormones need to be depleted before manifestation of drug effects ^[2]
Regimen types	Titrating regimen: start high → titrate down by TSH ^[3]; Block and replace: high-dose ATD + T4 replacement ^[3]

Side Effect	Frequency	Mechanism / Details
Skin rash / urticaria / pruritus	5% ^[2]	Allergy — trigger release of histamine — treated by antihistamine ^[2]
Agranulocytosis	0.1–0.5% ^[2]^[3]	Occurs within first 2–3 months; reversible; usually first 2 months; ↑with age ( > 40y) or high doses ^[3]; predicted by HLA-B38:02:01 allele (mainly found in Asian population)* ^[3]; presents with fever/sore throat while on ATD → advise to seek help immediately if any symptoms of infection ^[3]
Hepatotoxicity	Varies	Especially PTU, up to 1/3 associated with ↑ALT/AST but rarely associated with fulminant failure ^[3]; hepatic necrosis ^[2] possible with PTU
Teratogenicity	Rare	Aplasia cutis, choanal atresia (methimazole/carbimazole >> PTU) ^[3]; PTU is preferred in 1st trimester
Fever, arthritis/arthralgia	Uncommon	^[2]

Agranulocytosis — The Dreaded Complication

Agranulocytosis (0.1–0.5%) ^[2] is the most dangerous side effect. It typically presents with sudden-onset sore throat and fever. You MUST counsel every patient starting ATDs: "If you develop a sore throat, fever, or mouth ulcers, stop the medication and come to hospital IMMEDIATELY for a blood test (CBC)." If neutrophils are severely depressed, stop ATD permanently, give G-CSF and broad-spectrum antibiotics, and switch to an alternative treatment modality (RAI or surgery).

3C. Radioactive Iodine (RAI) — Definitive Treatment

This is often the preferred definitive treatment for toxic adenoma, particularly when there are no compressive symptoms (no "4C" indications for surgery).

For toxic adenoma, upfront RAI (over antithyroid drug) is preferred because of ↑iodine uptake ^[3].

Taken up and processed by thyroid gland in the same way as normal iodide — specificity to thyroid is due to preferential thyroid uptake via Na-I cotransporter → becomes incorporated into thyroglobulin → emits β-radiation in thyroid gland → destruction of thyroid gland — necrosis of follicular cells ^[2].

Let's break this down from first principles:

131I is administered orally (as sodium iodide solution or capsule).
It is absorbed from the GI tract into the blood.
The NIS (sodium-iodide symporter) on thyroid follicular cells avidly takes it up — just like normal iodine.
In a toxic adenoma, the autonomous nodule has HIGHLY active NIS (the constitutively active TSHR/Gsα pathway upregulates NIS expression). Meanwhile, the suppressed normal thyroid has LOW NIS activity (no TSH stimulation).
Result: 131I concentrates preferentially in the hot nodule, NOT in the surrounding normal tissue.
131I emits β-particles (electrons) with a path length of ~0.5–2 mm — enough to destroy the follicular cells of the nodule but with minimal damage to surrounding structures.
Over weeks to months, the nodule shrinks and loses its autonomous function → euthyroidism (or hypothyroidism).

This is why RAI is particularly elegant for toxic adenoma: the suppressed surrounding tissue does NOT take up the 131I significantly, so it is relatively spared → lower risk of post-RAI hypothyroidism compared to Graves' disease (where the whole gland takes up 131I).

Indication	Rationale
Definitive treatment of toxic adenoma (preferred when no 4C)	Nodule has high iodine uptake → excellent response; lower hypothyroidism risk than Graves'
Refractory to antithyroid medications ^[2]	ATDs cannot provide long-term cure for toxic adenoma
Relapse or contraindicated to surgery ^[2]	Alternative to surgery in high-surgical-risk patients
Ablation of residual tumour tissues after thyroidectomy ^[2] (for thyroid cancer, not toxic adenoma)	Different context — mentioned for completeness

Contraindication	Reason
Pregnancy ^[2]	Damage of thyroid gland of fetus ^[2] — the fetal thyroid begins concentrating iodine from ~12 weeks gestation; 131I would destroy it → congenital hypothyroidism (cretinism). Pregnancy test for patients with childbearing potential ^[2] must be done BEFORE treatment.
Breastfeeding ^[2]	Avoid breastfeeding since it is secreted in breastmilk ^[2] — NIS is also expressed in lactating breast tissue
Children and adolescents (relative contraindication) ^[2]	Avoid potential teratogenicity in young age ^[2] — growing tissues are more radiosensitive; theoretical concern about long-term radiation effects (though evidence for actual increased cancer risk is limited)
Active Graves' ophthalmopathy (moderate/severe)	Moderate/severe GO is a contraindication to RAI treatment ^[3] — RAI can worsen orbitopathy by increasing antigen release from destroyed thyroid cells → ↑TRAb flare. However, this is NOT relevant for toxic adenoma (no GO), so it is mentioned only for comparison.
Suspected thyroid malignancy	A cold nodule or suspicious features should be evaluated (FNAC/surgery) before RAI
Very large goitre with compressive symptoms	RAI works slowly (weeks–months); surgery provides immediate relief of compression

Before RAI ^[2]:

Discussion of treatment options and patient's consent
Instruct patients on post-therapy precautions and follow-ups
Avoid iodine-containing food, medicine (cough suppressant) or radiological contrast for ≥ 4 weeks before 131I therapy — exogenous iodine competes with 131I for NIS uptake, reducing efficacy
Avoid antithyroid medications for ≥ 4 weeks before 131I therapy — ATDs inhibit organification; if 131I is not organified, it washes out of the gland and does not deliver effective β-radiation
Symptomatic control of hyperthyroidism by propranolol — maintain β-blocker while waiting
Pregnancy test for patients with childbearing potential

After RAI ^[2]:

Symptomatic control of hyperthyroidism by propranolol — thyrotoxicosis may temporarily worsen as damaged follicular cells release stored hormone
Discharge home immediately and avoid close contact with others — the patient is temporarily radioactive (131I emits γ-rays as well as β-particles)
Safe contraception ≥ 6 months; avoid pregnancy and breastfeeding ≥ 6 months ^[2]

Outcome	Details
Cure rate	~80–90% after a single dose; may need repeat dose in 10–20%
Hypothyroidism	Transient = 3.5–28%; Permanent = 10–15% in first 2 years and 3%/year (due to late effects of radiation and lymphocytic infiltration and destruction of thyroid tissue) ^[2]. Lower for toxic adenoma than Graves' because the suppressed normal tissue is relatively spared.
Transient thyrotoxicosis	Radiation thyroiditis → release of stored hormone → worsening of thyrotoxicosis for 1–2 weeks. Usually mild and managed with β-blockers.
No effect on fertility; No effect on congenital malformations; No effect on increased cancer risk of offspring ^[2]	Reassuring long-term safety data

Why RAI is Particularly Effective for Toxic Adenoma

In toxic adenoma, the autonomous nodule has upregulated NIS (due to constitutive TSHR activation) while the surrounding normal tissue has downregulated NIS (due to TSH suppression). This creates a natural targeting mechanism — 131I is preferentially concentrated in the nodule and spares the normal gland. This is why: (1) The cure rate is high (~85–90% with single dose), (2) The risk of hypothyroidism is LOWER than in Graves' (where the whole gland takes up 131I), and (3) Upfront RAI is preferred for toxic adenoma because of ↑iodine uptake ^[3].

3D. Surgery (Thyroidectomy) — Definitive Treatment

Toxic adenoma: hemithyroidectomy (if no evidence of nodules in contralateral lobe) ^[6].

Feature	Details
Procedure	Hemithyroidectomy (= lobectomy + isthmusectomy) — removal of the lobe containing the toxic adenoma plus the isthmus
Why hemithyroidectomy, not total?	The contralateral lobe is normal (though suppressed by low TSH) and will resume function once the toxic nodule is removed → TSH recovers → normal lobe resumes hormone production → patient often becomes euthyroid without needing lifelong T4 replacement. This is a major advantage over total thyroidectomy.
When total thyroidectomy instead?	If there are nodules in the contralateral lobe (i.e. it's really a toxic MNG, not a solitary toxic adenoma); if concomitant thyroid cancer is suspected; Toxic MNG: total thyroidectomy ^[6]

Indications for thyroidectomy: 3Cs (or 4C) ^[3]:

(Cancer): Confirmed CA or suspicious FNAC (Bethesda IV–VI) ^[3]
Compressive symptoms: Dysphagia, dysphonia, dyspnoea or retrosternal goitre ^[3]
Cannot be treated medically: Frequent relapses, require definitive Tx (when RAI unsuitable or large goitre > 80g) ^[3]
Cosmesis ^[3]

Benign thyroid nodule — indications of treatment ^[8]:

Symptomatic (size of goitre/nodule)
Increase in goitre size
Trachea compression or deviation
Retrosternal extension
Suspected malignancy
Cosmetic considerations/patient wish

Specific to toxic adenoma, surgery is preferred when:

Large nodule with compressive symptoms (RAI works too slowly for compression)
Suspicion of co-existing malignancy (e.g. additional cold nodule)
Patient preference (some patients prefer a single definitive procedure)
Pregnancy — if ATDs are not tolerated (RAI is absolutely contraindicated in pregnancy)
Children/adolescents — where RAI is relatively contraindicated

Pre-op preparation in thyrotoxic patients undergoing thyroid surgery ^[6] — this is critical to prevent perioperative thyroid storm:

Step	Rationale
Achieve euthyroid state with ATDs	Patients should be brought to euthyroid before surgery to avoid possible thyroid storm ^[2]. Typically carbimazole for 4–6 weeks until TFTs normalise.
β-Blocker	Continue until and including the morning of surgery to control heart rate and prevent adrenergic crisis
Lugol's iodine (potassium iodide solution) — 7–10 days pre-op	High-dose iodine induces the Wolff-Chaikoff effect → transiently ↓organification → ↓hormone synthesis AND ↓thyroid vascularity (makes the gland less vascular and easier to operate on). Must only be given AFTER ATDs have taken effect (otherwise the iodine would become substrate for new hormone synthesis).
Check calcium and vitamin D	Baseline for comparison post-op (risk of hypoparathyroidism)
Direct laryngoscopy	Document vocal cord function pre-operatively (baseline for comparison if RLN injury suspected post-op)

Complication	Mechanism	Frequency
Thyroid storm ^[2]	Manipulation of a hyperthyroid gland during surgery → massive release of stored T3/T4 into the bloodstream. Prevented by rendering patient euthyroid pre-op.	Rare if pre-op preparation adequate
Haemorrhage ^[2]	Compression and oedematous effect compresses on trachea ^[2] — post-op haematoma can cause airway compromise; this is a surgical emergency requiring immediate wound opening at the bedside
Recurrent laryngeal nerve (RLN) injury ^[6]	Unilateral → hoarseness (vocal cord paralysis on one side); Bilateral → stridor and airway obstruction (both cords in paramedian position) — requires emergency intubation/tracheostomy	Temporary: 2–5%; Permanent: ~1% in experienced hands
Hypoparathyroidism ^[2]^[6]	Inadvertent removal or devascularisation of parathyroid glands → ↓PTH → hypocalcaemia → perioral numbness, Chvostek's/Trousseau's signs, tetany	Temporary: 10–20%; Permanent: 1–2% (much lower with hemithyroidectomy than total)
Hypothyroidism	After hemithyroidectomy: usually the contralateral lobe recovers function; after total thyroidectomy: thyroid failure (100%) ^[6] → lifelong T4 replacement	HemiT: ~5–10%; TT: 100%

Hemithyroidectomy Advantage in Toxic Adenoma

Because toxic adenoma is treated with hemithyroidectomy (not total thyroidectomy), the risks of hypoparathyroidism and bilateral RLN injury are dramatically lower than in total thyroidectomy — you are only operating on one side of the neck. Additionally, most patients do NOT need lifelong T4 replacement because the contralateral lobe resumes normal function once TSH recovers.

These are newer, less invasive alternatives to surgery for benign thyroid nodules including toxic adenoma. They are not yet first-line but are increasingly available.

Technique	Mechanism	Notes
Radiofrequency ablation (RFA)	Thermal destruction of the nodule via a needle electrode inserted under USG guidance	Effective for volume reduction; can cure small toxic adenomas; non-operative measures, e.g. RFA, HIFU, ethanol ablation (not 100% curative) ^[3]
High-intensity focused ultrasound (HIFU)	Non-invasive thermal ablation using focused ultrasound energy	HIFU can be done for benign nodule < 5cm ^[3]; no skin puncture required
Percutaneous ethanol injection (PEI)	Direct injection of ethanol into the nodule → chemical destruction	More effective for cystic nodules; less effective for solid toxic adenomas

These are generally considered when the patient refuses or is unfit for both RAI and surgery.

Not all toxic adenomas cause overt thyrotoxicosis. Small autonomous nodules may present as subclinical hyperthyroidism (↓TSH, normal fT4/T3) ^[3].

Management is guided by the degree of TSH suppression and the patient's risk factors ^[3]:

Scenario	Management	Rationale
TSH < 0.1 mU/L	Workup + treat ^[3]	Strongly suppressed TSH carries ↑risk of AF (1.68×), osteoporosis, IHD, HF ^[3]. Treatment warranted.
TSH 0.1–0.4 mU/L in high-risk patient (elderly, at risk of osteoporosis, underlying IHD)	Workup + treat ^[3]	Even mildly suppressed TSH increases cardiovascular and bone risk in vulnerable patients
TSH 0.1–0.4 mU/L in low-risk patient	Observe + monitor otherwise ^[3]	Risk of progression to overt hyperthyroidism is ~0.5–8%/year ^[3]; monitor TFT Q6–12 months

Although thyroid storm can occur from any cause of thyrotoxicosis, it is relevant to toxic adenoma — particularly if a patient with an untreated toxic adenoma undergoes surgery, infection, or iodine load.

Thyrotoxic crisis (thyroid storm): rare but life-threatening (10% mortality, medical emergency) ^[5]^[12].

Setting ^[5]:

Longstanding untreated hyperthyroidism
Acute infection, thyroid and non-thyroid surgery, trauma, childbirth in previously untreated/undertreated hyperthyroidism
Withdrawal of antithyroid drugs
Shortly after treatment procedures (subtotal thyroidectomy or RAI)
Acute iodine load, e.g. amiodarone

Treatment ^[5]^[12]:

Close monitoring: may need CVP ± ICU care
Supportive Tx: CHF/AF (O2, digoxin/diuretics ± inotropes); hyperthermia (paracetamol, physical cooling); dehydration (IVF, IV thiamine)
Non-selective β-blocker/CCB to ↓adrenergic S/S
Immediate thionamide to ↓thyroid hormone synthesis — PTU preferred for its blocking effect on T4-to-T3 conversion ^[5]^[12]
Glucocorticoids to ↓peripheral conversion of T4 → T3 ^[5]
Iodine after ≥1 hour to rapidly ↓thyroid hormone release ^[5]^[12]:
- Mechanism: large doses of exogenous iodine inhibit organification of iodine in thyroid gland transiently due to Wolff-Chaikoff effect ^[5]
- Must be given ≥1h after first dose of thionamide → prevent the iodine from being used as substrate for new hormone synthesis ^[5]^[12]
- Choices: 6–8 drops Lugol's/SSKI PO Q6–8H, Oragrafin, IV NaI ^[12]
Bile acid sequestrant to ↓enterohepatic cycling of T4 and ↑excretion ^[5] — adjunctive
Other choices: plasmapheresis, charcoal haemoperfusion for desperate cases ^[5]

Factor	Favours RAI	Favours Surgery
Compressive symptoms	✗ (too slow)	✓ (immediate decompression)
Nodule size	Small–moderate ( < 4 cm)	Large ( > 4 cm) — may need larger RAI dose with diminishing returns
Suspicion of malignancy	✗ (need histology)	✓ (provides tissue for histological diagnosis)
Pregnancy	Contraindicated ^[2]	✓ (if ATDs not tolerated — 2nd trimester preferred)
Children/adolescents	Relative contraindication ^[2]	✓ (preferred)
Surgical fitness	✓ (non-invasive)	Requires general anaesthesia fitness
Graves' ophthalmopathy	Contraindication if moderate/severe GO ^[3]	✓
Patient preference	Non-surgical, outpatient	Single definitive procedure
Contralateral nodules	May treat only hot tissue	Can perform total thyroidectomy if bilateral disease
Speed of effect	Weeks–months	Immediate
Hypothyroidism risk	Lower (~10–15% at 2 years) ^[2]	HemiT: ~5–10%; TT: 100%
Need for lifelong T4	Less likely (normal tissue spared)	Less likely after hemiT; certain after TT

After RAI	After Hemithyroidectomy
TFT Q4–6 weeks for first 3–6 months	TFT at 6 weeks, then Q3–6 months for 1 year
Then TFT Q3–6 months for first year	Serum Ca²⁺ check post-op Day 1 (hypoparathyroidism screening)
Annual TFT thereafter (lifelong)	Voice assessment post-op (RLN function)
If hypothyroid → start levothyroxine	If hypothyroid → start levothyroxine (less common after hemiT)
If persistent thyrotoxicosis at 6 months → consider repeat RAI or surgery	Histology review to confirm benign adenoma

High Yield Summary

Toxic adenoma requires definitive treatment — ATDs are bridge therapy only because they recur upon discontinuation ^[6]. This is fundamentally different from Graves' disease where ATDs are first-line.
Management: β-blocker for symptomatic relief → ATDs as bridge → definitive Tx (RAI or surgery) ^[3]^[5].
RAI is often preferred for toxic adenoma because ↑iodine uptake in the autonomous nodule ^[3] with sparing of suppressed normal tissue → effective ablation with lower hypothyroidism risk than Graves'. Contraindicated in pregnancy and breastfeeding ^[2].
Surgery: hemithyroidectomy (if no evidence of nodules in contralateral lobe) ^[6]. Preferred when compressive symptoms (4C), suspected malignancy, pregnancy with ATD intolerance, or patient preference.
Pre-op preparation is critical: achieve euthyroid with ATDs + β-blocker + Lugol's iodine (7–10 days pre-op) to prevent thyroid storm ^[2]^[6].
ATD side effects to counsel: agranulocytosis (0.1–0.5%) — advise patient to seek help immediately if sore throat/fever ^[3]; hepatotoxicity (esp PTU); rash (5%) ^[2]^[3].
RAI preparation: Avoid iodine-containing food/medicine/contrast ≥ 4 weeks before; avoid ATDs ≥ 4 weeks before; pregnancy test; safe contraception ≥ 6 months after ^[2].
Thyroid storm: medical emergency (10% mortality). Treat with β-blocker → PTU → glucocorticoids → iodine (≥1h after PTU) → supportive ^[5]^[12].

Active Recall - Management of Toxic Adenoma

^[2] Senior notes: felixlai.md (Section VI — Treatment of hyperthyroidism, Case study — RAI preparation) ^[3] Senior notes: Ryan Ho Endocrine.pdf (p13 — Mx; p17 — nodule management; p21 — scintigraphy and Mx for benign goitre; p24 — ATDs; p28 — GO management) ^[5] Senior notes: Adrian Lui Pediatrics.pdf (p272 — Mx; p273 — thyroid storm) ^[6] Senior notes: maxim.md (Thyrotoxicosis indications table; toxic adenoma hemithyroidectomy; pre-op preparation) ^[8] Lecture slides: GC 177. A thyroid nodule benign thyroid nodules; thyroid cancer.pdf (p14 — indications of treatment for benign thyroid nodules) ^[12] Senior notes: Ryan Ho Fundamentals.pdf (p422 — Mx; thyroid storm management)

Framing the Problem

Complications of toxic adenoma arise from three distinct sources:

Complications of the disease itself — i.e. the consequences of untreated or undertreated thyrotoxicosis and the local effects of the nodule
Complications of antithyroid drug therapy — the bridge treatment
Complications of definitive treatment — RAI or surgery

Each has a clear pathophysiological basis. Let me walk through them systematically.

1. Complications of Untreated / Undertreated Thyrotoxicosis

If a toxic adenoma is not treated (or inadequately controlled), the persistent excess of T3/T4 causes progressive end-organ damage. The heart and bones are the two organs most vulnerable to chronic thyroid hormone excess.

The cardiovascular system is the primary target of thyrotoxicosis-related morbidity and mortality, especially in older patients.

Complication	Pathophysiology	Clinical Details
Atrial fibrillation (AF)	T3 upregulates β1-adrenergic receptors in atrial myocytes → shortens atrial refractory period → ↑susceptibility to re-entrant circuits. Also ↑automaticity of atrial pacemaker cells.	Occurs in ~10–15% of thyrotoxicosis; much more common in elderly. Classically AF + multinodular goitre in elderly ^[3] applies equally to toxic adenoma in older patients. Risk is 1.68× even in subclinical hyperthyroidism ^[3]. AF may be the PRESENTING feature of occult toxic adenoma ("apathetic thyrotoxicosis").
High-output heart failure	↑cardiac output (↑HR + ↑contractility + ↓SVR from peripheral vasodilation) → sustained volume overload → ventricular dilatation → eventual systolic and diastolic dysfunction. T3 also directly affects myocardial gene expression (↑myosin heavy chain α, ↑SERCA2 calcium pump).	Presents with dyspnoea, orthopnoea, peripheral oedema, elevated JVP. Deterioration of CVS disease by thyrotoxicosis — ↑workload of heart and worsens ischaemic symptoms — angina / arrhythmias / cardiac failure ^[2].
Worsening of pre-existing ischaemic heart disease	↑myocardial oxygen demand (↑HR × ↑contractility) in the setting of fixed coronary artery stenosis → supply-demand mismatch → ischaemia.	Angina / arrhythmias / cardiac failure ^[2]. This is particularly dangerous in elderly patients who may have occult CAD.
Systolic hypertension / widened pulse pressure	↑cardiac output + ↓SVR → systolic BP rises while diastolic falls	May contribute to LVH and cardiovascular events over time

Why AF is Such a Big Deal in Elderly Thyrotoxicosis

In an older patient with an undiagnosed toxic adenoma, the first presentation may be new-onset AF — not palpitations or tremor. This is "apathetic thyrotoxicosis" where the classic hyperadrenergic symptoms are blunted. Always check TFTs in any patient with new-onset AF — if TSH is suppressed, you've found the cause. Restoring euthyroidism may revert AF to sinus rhythm in up to 60% of patients if treated within a few months.

Complication	Pathophysiology	Clinical Details
Osteoporosis	T3 excess → ↑osteoclastic bone resorption (T3 directly stimulates osteoclast activity and upregulates RANKL) → net bone loss. ↑bone resorption markers, ↓bone mineral density.	Subclinical hyperthyroidism a/w osteoporosis: ↑bone resorption, ↓bone density ^[3]. Particularly concerning in postmenopausal women who already have ↓oestrogen-mediated bone protection. Fracture risk is increased.
Hypercalcaemia (mild)	↑osteoclastic bone resorption releases calcium into the blood	Usually mild and asymptomatic; resolves with treatment of thyrotoxicosis
Glucose intolerance / worsening diabetes	T3 → ↑hepatic gluconeogenesis, ↑glycogenolysis, ↑insulin resistance; also ↑GI absorption of glucose	May unmask latent diabetes or worsen glycaemic control in existing diabetics
Weight loss and muscle wasting	T3 accelerates protein catabolism in skeletal muscle and lipolysis in adipose tissue; BMR increased 20–60% above normal	Proximal myopathy, sarcopenia, fatigue; may be mistaken for malignancy in the elderly

This is a specific complication particularly relevant to the Hong Kong/Asian population:

↑Na⁺/K⁺-ATPase activity (T3 upregulates pump expression) + ↑insulin release (especially after carbohydrate load) → massive intracellular shift of K⁺ → profound hypokalaemia → muscle paralysis
Up to 2% among Asian patients with hyperthyroidism ^[3]; overwhelmingly young males
Can occur from ANY cause of thyrotoxicosis, including toxic adenoma
Cardiac arrhythmia risk from severe hypokalaemia (mean serum K⁺ ~2.1 mmol/L) ^[3]

Thyrotoxic crisis (thyroid storm): rare but life-threatening (10% mortality, medical emergency) ^[5].

This is the most feared acute complication. Although rare, it can occur in a patient with an untreated toxic adenoma who encounters a precipitant.

Setting ^[5]:

Longstanding untreated hyperthyroidism
Acute infection, thyroid and non-thyroid surgery, trauma, childbirth in previously untreated/undertreated hyperthyroidism
Withdrawal of antithyroid drugs
Shortly after treatment procedures (subtotal thyroidectomy or RAI)
Acute iodine load, e.g. amiodarone

Pathophysiology ^[2]: Thyroid storm develops in patients with longstanding untreated hyperthyroidism which is precipitated by acute event such as surgery, trauma or infection → rapid ↑ in serum thyroid hormone levels leading to increased response to sympathetic inputs from catecholamine (adrenaline/noradrenaline) by permissive effect → leads to cardiovascular symptoms including hyperpyrexia, tachycardia, hypertension and followed by heart failure with hypotension and arrhythmia ^[2].

S/S: exaggeration of usual hyperthyroid symptoms to a severe or even life-threatening extent ^[5]:

CVS: tachycardia > 140/min, AF, high output failure
Hyperpyrexia: may reach > 40°C
CNS disturbance: agitation, anxiety, delirium, psychosis, stupor, coma

Complication	Pathophysiology
Haemorrhage into the nodule	Spontaneous bleeding into the adenoma → sudden painful enlargement; may cause acute compression of trachea/oesophagus
Compressive symptoms (large nodule)	Dysphagia (oesophagus), dyspnoea/stridor (trachea), dysphonia (RLN — very rare with benign adenomas)
Retrosternal extension	Large nodule grows inferiorly behind the sternum → superior vena cava syndrome, tracheal compression, impossible to assess by USG alone → requires CT ^[6]

Malignant Transformation — A Non-Issue

A commonly asked question: "Can a toxic adenoma become malignant?" The answer is: virtually never. Toxic adenomas have TSHR/Gsα mutations that drive differentiation and function, not dedifferentiation. The risk of malignancy in a confirmed hot nodule is < 1–2%. Follicular adenoma is NOT a risk factor of follicular CA ^[6]. The somatic mutations in toxic adenoma (TSHR, Gsα) are fundamentally different from cancer-driving mutations (BRAF, RAS, RET/PTC).

These are iatrogenic complications — side effects of the bridge treatment.

Complication	Frequency	Mechanism	Clinical Details
Skin rash / urticaria / pruritus	5% ^[2]	Allergy — trigger release of histamine ^[2]	Usually mild; treated by antihistamine ^[2]; if severe, switch ATD or change treatment modality
Agranulocytosis	0.1–0.5% ^[2]^[3]	Immune-mediated destruction of neutrophil precursors in bone marrow	Occurs within first 2–3 months of treatment ^[2]. Predicted by HLA-B38:02:01 allele (mainly found in Asian population)* ^[3]. Presents with fever/sore throat while on ATD ^[3]. Management: stop ATD immediately, urgent CBC, broad-spectrum antibiotics, G-CSF, switch to non-ATD definitive treatment. Reversible ^[3].
Hepatotoxicity	Variable	PTU → direct hepatocellular toxicity (idiosyncratic immune-mediated hepatocyte necrosis); Carbimazole → cholestatic pattern (milder)	Especially PTU, up to 1/3 associated with ↑ALT/AST but rarely associated with fulminant failure ^[3]. Hepatic necrosis ^[2] possible with PTU. Baseline LFT should be checked before starting ATDs.
Teratogenicity	Rare	Direct embryotoxicity during organogenesis (1st trimester)	Aplasia cutis, choanal atresia (methimazole/carbimazole >> PTU) ^[3]. PTU is preferred in 1st trimester because of ↓teratogenicity ^[3].
Fever, arthritis/arthralgia	Uncommon	Immune-mediated	^[2] — mild, often self-limiting
ANCA-positive vasculitis	Very rare	PTU-associated; drug induces anti-MPO antibodies	Glomerulonephritis, pulmonary haemorrhage; discontinue PTU immediately

The Agranulocytosis Counselling Point

Every patient starting ATDs MUST be counselled: "If you develop a sore throat, fever, or mouth ulcers, stop the medication immediately and come to hospital for an urgent blood test." This is a board exam favourite. Failure to counsel = medicolegal risk. Agranulocytosis is rare but potentially fatal if not recognised early (overwhelming sepsis from neutropaenic patients).

Complication	Frequency	Mechanism	Clinical Details
Hypothyroidism	Transient = 3.5–28%; Permanent = 10–15% in first 2 years and 3%/year thereafter ^[2]	Late effects of radiation and of lymphocytic infiltration and destruction of thyroid tissue ^[2] — 131I destroys follicular cells; if enough normal tissue is damaged alongside the nodule, hormone production falls below requirements.	Lower incidence in toxic adenoma than Graves' (because the suppressed normal tissue takes up less 131I). Requires lifelong levothyroxine replacement if permanent. Monitor TFT Q4–6 weeks then annually.
Radiation thyroiditis (transient worsening)	~3% ^[3]	Acute radiation-induced inflammation → release of stored T3/T4 from damaged follicular cells	Transient worsening of thyrotoxicosis 1–2 weeks post-RAI; managed with β-blockers. Usually self-limiting.
Transient neck pain and swelling	Common	Inflammatory oedema of irradiated thyroid tissue	Mild, self-limiting. NSAIDs for symptom relief.
Sialadenitis (salivary gland inflammation)	Occasional	NIS is also expressed in salivary gland ductal cells → 131I uptake in salivary glands → radiation damage	Dry mouth, parotid swelling. Managed with sialogogues (lemon drops), hydration. More common with higher 131I doses (e.g. cancer ablation doses).
Worsening of Graves' ophthalmopathy	N/A for toxic adenoma	RAI → ↑antigen release from destroyed thyroid → ↑TRAb flare → worsening GO. Moderate/severe GO is a contraindication to RAI ^[3].	This complication is specific to Graves' disease and does NOT occur in toxic adenoma (no TRAb, no GO). Mentioned for comparison only.

Reassurance ^[2]: No effect on fertility. No effect on congenital malformations. No effect on increased cancer risk of offspring ^[2] — long-term safety data for therapeutic 131I is very reassuring.

4. Complications of Thyroidectomy (Hemithyroidectomy)

Surgery for toxic adenoma is hemithyroidectomy (if no evidence of nodules in contralateral lobe) ^[6]. Complications are classified by timing.

Complication	Mechanism	Details
Intraoperative bleeding ^[2]	Thyroid gland is highly vascular (superior and inferior thyroid arteries); handling inflamed thyrotoxic gland increases risk	Controlled intraoperatively with careful technique. Lugol's iodine pre-op reduces vascularity ^[6].
Thyroid storm ^[2]	Thyroid storm develops in patients with longstanding untreated hyperthyroidism precipitated by acute event such as surgery ^[2]. Manipulation of a hyperthyroid gland → massive release of stored T3/T4.	Prevented by rendering patient euthyroid before surgery with ATDs + β-blocker + Lugol's ^[6].
Oesophageal injury ^[2]	Posterior dissection near the oesophagus	Rare; recognised by saliva in wound or post-op mediastinitis
Tracheal injury ^[2]	Very close proximity of thyroid to trachea	Rare; may require repair
Superior laryngeal nerve (SLN) injury ^[2]	SLN supplies the cricothyroid muscle which lengthens (tenses) the vocal cord to produce high-pitched sound ^[2]	Presents with vocal fatigue and changes in voice quality ^[2] — patient cannot project voice or sing high notes. Important to ask if the patient is a professional singer pre-op ^[3].
Recurrent laryngeal nerve (RLN) injury ^[2]^[3]	RLN supplies all intrinsic muscles of larynx except cricothyroid ^[2]	Can be transient (tractional) or permanent (transection) ^[3]. See below for details.

Complication	Mechanism	Details
Haematoma formation ^[2]^[3]	Post-operative bleeding into the surgical bed	Potentially fatal if compression on airways ^[2]. Usually in paratracheal region below strap muscles → causes venous obstruction → acute laryngeal oedema → risk of airway compromise ^[3]. S/S: large, tense, firm immobile neck swelling + SOB ^[3]. Management: cut subcuticular stitches and stitches holding strap muscles (evacuate all blood) → call seniors for intubation ^[3]. This is a surgical emergency — do NOT wait for the operating theatre. Open the wound at the bedside.
Wound infection ^[2]	Contamination of surgical wound	Usually mild; treated with antibiotics. Risk increased with haematoma.
Tracheomalacia ^[2]^[3]	Can arise post-operatively due to degeneration of cartilage following removal of compression by large goitre ^[3] — the tracheal rings were chronically compressed and became softened; once the external support (goitre) is removed, the airway may collapse	Rare; presents with stridor post-extubation. May require temporary intubation or tracheostomy.
Dysphagia ^[3]	Reason unclear, usually resolves ^[3] — likely related to oedema and surgical manipulation near the oesophagus	Usually self-limiting within days to weeks

Post-Thyroidectomy Haematoma — The Bedside Emergency

Post-operative haematoma is uncommon but potentially fatal ^[3]. The key teaching point: if a patient develops a tense neck swelling with stridor after thyroidectomy, you must open the wound at the bedside immediately — do NOT wait for the operating theatre, do NOT try to intubate first (the laryngeal oedema may make intubation impossible). Cut the subcuticular stitches and stitches holding strap muscles → evacuate all blood → then call for senior help and anaesthetic support. This buys time for the airway oedema to decompress.

Complication	Mechanism	Details
Hypoparathyroidism → Hypocalcaemia	MOST common complication ^[2] of thyroidectomy. Inadvertent removal, devascularisation, or contusion of parathyroid glands → ↓PTH → ↓Ca²⁺. Often due to compromise of inferior thyroid artery ^[3] (which supplies both the thyroid and parathyroid glands).	Risk: 1–4% permanent (esp in cancer surgery), 10–20% transient (esp in ischaemia) ^[3]. Much lower risk with hemithyroidectomy (only operating on one side → at most 2 of 4 parathyroids at risk, and usually 0 are removed). Check serum corrected Ca²⁺ level or PTH level postoperatively ^[2].
		Presents with symptoms of hypocalcaemia: perioral and acral paraesthesia, carpopedal spasm, muscle spasms and cramps, Trousseau's sign and Chvostek's sign ^[2]. Mnemonic: CATS GO NUMB (Convulsion, Arrhythmia, Tetany, laryngoSpasm, NUMBNESS — perioral, distal) ^[3].
		ECG: long QT ± arrhythmia ^[3].
		Management: Fast replacement — IV 10–20 mL of 10% calcium gluconate over 10 mins (slow bolus); Replacement — calcium carbonate + calcitriol (vitamin D) ^[2].
Hungry bone syndrome	May occur in those with pre-op hyperthyroidism → pre-op high bone turnover with sudden ↓PTH → ↑↑↑bone ossification → sudden hypocalcaemia ^[3]. When the thyrotoxicosis is abruptly reversed post-operatively, the previously hyperactive osteoclasts suddenly become quiescent while osteoblasts "catch up" — bones avidly take up calcium from the blood.	Can cause profound hypocalcaemia even more severe than hypoparathyroidism alone. Requires aggressive calcium and vitamin D supplementation. Monitor Ca²⁺ closely in patients who were thyrotoxic pre-operatively.
Recurrent laryngeal nerve injury (permanent)	Transection or severe traction injury during dissection	Unilateral: treated by medialization (inject fat into paralysed vocal cord to improve apposition) ^[3]. Bilateral: dyspnoea + stridor upon extubation → require immediate re-tube ± tracheostomy ^[3]. Permanent injury < 1% in experienced hands. ↑risk of aspiration pneumonia ^[2] due to impaired glottic closure.
Hypothyroidism	Loss of functional thyroid tissue	After hemithyroidectomy for toxic adenoma: usually the contralateral lobe recovers (TSH rises as the autonomous source is removed → stimulates the previously suppressed lobe). ~5–10% may develop hypothyroidism if the contralateral lobe was severely atrophied or had subclinical Hashimoto's. After total thyroidectomy: thyroid failure (100%) ^[6] → lifelong T4 replacement.
Recurrence ^[2]	Regrowth or persistent autonomous tissue	Very rare after hemithyroidectomy for solitary toxic adenoma (the entire nodule is removed with the lobe). More relevant for subtotal thyroidectomy or toxic MNG.
Hypertrophic scar and keloid formation ^[2]	Wound healing abnormality; more common in certain skin types	Cosmetic concern; managed with silicone sheets, steroid injections, or revision surgery

Source of Complication	Specific Complications
Untreated thyrotoxicosis	AF, high-output HF, angina, osteoporosis, fractures, thyrotoxic periodic paralysis (TPP — Asians), thyroid storm, glucose intolerance, muscle wasting
Antithyroid drugs	Agranulocytosis (0.1–0.5%), hepatotoxicity (esp PTU), skin rash (5%), teratogenicity, arthralgia, ANCA vasculitis (rare, PTU)
Radioactive iodine	Hypothyroidism (10–15% at 2 years), radiation thyroiditis (transient worsening), sialadenitis, neck pain
Surgery (hemithyroidectomy)	Haematoma (airway emergency), RLN injury (hoarseness or stridor), SLN injury (voice quality), hypoparathyroidism/hypocalcaemia, hungry bone syndrome, tracheomalacia, hypothyroidism (5–10%), wound infection, scar

	Surgery	Anti-thyroid drugs	131I therapy
Relapse	Low	High (70% after 1 year)	Low / Intermediate
Risk of hypothyroidism	Intermediate / High	Low	Intermediate / High (10–15% in first 2 years, 3% risk onwards)
Other long-term complications	Significant morbidity	Rare	Rare
Ease of treatment and cost	Intermediate	Least favourable	Simple and easy
Onset of therapeutic effect	Immediate	Days / Weeks	Months (2–3 months)

High Yield Summary

Cardiovascular complications are the most important systemic consequences of untreated toxic adenoma: AF (10–15%, higher in elderly, risk 1.68× even in subclinical disease), high-output heart failure, and worsening IHD.
Osteoporosis from ↑osteoclastic bone resorption is a significant long-term risk, particularly in postmenopausal women with even subclinical hyperthyroidism.
Thyroid storm ^[5] is the most feared acute complication (10% mortality) — precipitated by surgery, infection, iodine load, or ATD withdrawal in untreated patients.
Agranulocytosis (0.1–0.5%) ^[2]^[3] from ATDs presents with fever/sore throat — counsel ALL patients to stop medication and seek immediate blood test if these symptoms develop.
Post-RAI hypothyroidism is the main long-term complication of 131I but is lower in toxic adenoma than Graves' because the suppressed normal tissue is relatively spared.
Post-thyroidectomy haematoma ^[2]^[3] is a surgical emergency — open the wound at the bedside to relieve airway compression before attempting intubation.
Hypoparathyroidism is the MOST common late complication ^[2] of thyroidectomy — risk is much lower with hemithyroidectomy than total. Check post-op Ca²⁺ and PTH. Symptoms: CATS GO NUMB ^[3].
Hungry bone syndrome ^[3] can cause profound post-op hypocalcaemia in previously thyrotoxic patients — monitor closely.
Malignant transformation of a toxic adenoma is essentially non-existent — hot nodules are almost never malignant ^[5]; follicular adenoma is NOT a risk factor of follicular CA ^[6].

Active Recall - Complications of Toxic Adenoma

^[2] Senior notes: felixlai.md (Section V — Complications of thyroidectomy; Section VI — Treatment of hyperthyroidism; Case study — RAI complications) ^[3] Senior notes: Ryan Ho Endocrine.pdf (p17 — subclinical hyperthyroidism complications; p22 — pre-op preparation and complications; p24 — ATD side effects; p32 — toxic MNG complications) ^[5] Senior notes: Adrian Lui Pediatrics.pdf (p273 — thyroid storm) ^[6] Senior notes: maxim.md (Thyrotoxicosis management table; hemithyroidectomy; thyroid cancer — follicular adenoma not a risk factor)

Toxic Adenoma

1. Definition

2. Epidemiology

Prevalence and Incidence

Demographics

Risk Factors

3. Anatomy and Function — The Thyroid Gland

Gross Anatomy

Histology — The Functional Unit

The TSH Receptor (TSH-R) — Critical to Understanding Toxic Adenoma

4. Etiology and Pathophysiology

The Core Problem: Somatic Gain-of-Function Mutations

Pathophysiological Cascade

Natural History: From Subclinical to Overt

Why a Toxic Adenoma is Benign (and Why Hot Nodules Are Almost Never Malignant)

5. Classification

Within the Spectrum of Thyrotoxicosis

Classification of Goitre (Lecture Slide)

Classification of Thyroid Nodules [1][6]

Classification by Functional Status (Scintigraphy)

6. Clinical Features

General Principle

6A. Symptoms

Local Symptoms (from the Nodule)

Systemic Symptoms of Thyrotoxicosis

6B. Signs

Local Signs (Thyroid Examination)

Systemic Signs of Thyrotoxicosis

Signs ABSENT in Toxic Adenoma (Specific to Graves' Disease)

7. Approach to a Patient with Suspected Toxic Adenoma

Clinical Scenario

Step-by-Step Clinical Approach

8. Summary of Pathophysiology → Clinical Features Connection

Active Recall - Toxic Adenoma: Definition, Epidemiology, Etiology, Pathophysiology and Clinical Features

References

Framing the Problem

A. Differential Diagnosis of Thyrotoxicosis (↓TSH with ↑fT4/T3)

B. Differential Diagnosis of a Thyroid Nodule

C. The Critical Overlap: Thyrotoxicosis + Thyroid Nodule

D. Differentiating Toxic Adenoma from Its Closest Mimics

1. Toxic Adenoma vs Graves' Disease

2. Toxic Adenoma vs Toxic MNG

3. Toxic Adenoma vs Thyroid Carcinoma (Cold Nodule)

4. Toxic Adenoma vs Subacute (De Quervain's) Thyroiditis

5. Toxic Adenoma vs Factitious Thyrotoxicosis

E. Diagnostic Algorithm — Approach to Thyrotoxicosis with a Thyroid Nodule

F. Red Flags — When a "Toxic Adenoma" May Not Be What It Seems

Active Recall - Differential Diagnosis of Toxic Adenoma

Diagnostic Criteria, Diagnostic Algorithm, and Investigation Modalities for Toxic Adenoma

1. Diagnostic Criteria for Toxic Adenoma

2. Comprehensive Diagnostic Algorithm

3. Investigation Modalities — Detailed Breakdown

3A. Blood Tests

Thyroid Function Tests (TFTs)

Other Confounding Factors to Consider [3]

Thyrotropin Receptor Antibodies (TRAb)

3B. Thyroid Scintigraphy (Radionuclide Scan)

Principles [11]

Radiopharmaceuticals [11]

Indications [5][10][11]

Scintigraphy Patterns and Interpretation [5][8]

3C. Thyroid Ultrasound (USG)

Role in Toxic Adenoma [3][6]

Typical USG Appearance of a Toxic Adenoma

Sonographic Features Suspicious for Malignancy [10][12]

3D. Fine Needle Aspiration Cytology (FNAC)

When FNAC IS and IS NOT Needed

Bethesda Classification [10][3][12]

3E. Additional / Selective Investigations

3F. Investigations NOT Required in Toxic Adenoma

4. Summary: Routine vs Selective Investigations

5. Putting It All Together — Complete Diagnostic Pathway for Toxic Adenoma

Active Recall - Diagnosis and Investigation of Toxic Adenoma

References

Management of Toxic Adenoma

1. Overview of Management Modalities

2. Management Algorithm

3. Treatment Modalities — Detailed Breakdown

3A. Symptomatic Control: β-Blockers

3B. Antithyroid Drugs (ATDs) — Bridge Therapy